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Patient adherence to drug therapies remains an obstacle to realizing their full 
therapeutic benefit.  Sustained release formulations may decrease frequency of 
administration, potentially improving patient adherence. 
Implants may decrease dosing frequency to once every 5 years.  However, most 
polymers used today are hydrophobic, limiting drug properties suitable for development.  
Thermoplastic poly(urethanes) (TPUs) form pores upon hydration, offering a different 
release mechanism.  We sought to assess the range of drug diffusion rates achieved by 
varying hydrophilic-to-hydrophobic TPU ratio compared with poly(ethylene-co-vinyl 
acetate) (EVA) crystallinity; investigate the effect of drug physicochemical properties on 
permeability through membranes of varying TPU composition; visualize microstructural 
changes to the membrane across the TPU composition range; and characterize the 
membrane microstructure. 
Emtricitabine exhibited a >200-fold broader permeability range across the TPU 
blends than EVA grades.  Varying hydrophilic content of the TPU mixture between 0-
25% (w/w) led to a negligible permeability change, whereas a >100-fold permeability 
 viii 
change occurred between 50-55% (w/w).  We observed a correlation between drug 
hydrophobicity and its permeability through hydrophobic-rich TPU.  Conversely, drugs 
diffused through hydrophilic-rich TPU at similar rates, regardless of properties.  Imaging 
revealed significant microstructure differences between hydrophobic-rich and 
hydrophilic-rich TPU, supporting that hydrophilic polymer domains form a continuous 
network above 55% (w/w) hydrophilic TPU.  The large hydrophilic TPU equivalent pore 
radius suggests that it may modify the release of small molecular weight drugs and 
macromolecules.   
Gastroretentive formulations may reduce dosing frequency of medications 
otherwise taken up to 5 times per day.  Acyclovir is a short half-life drug with poor 
colonic absorption, and conventional controlled release formulations are unable to 
decrease dosing frequency.  We developed a modified-release acyclovir matrix tablet and 
surrounded it with a hydrophilic poly(urethane) layer.  When hydrated, the 
poly(urethane) swells to a size near to or beyond the relaxed pylorus diameter, without 
affecting drug release rate.   
We demonstrated that the formulation is retained in the stomach for extended 
durations as it slowly releases drug, allowing for similar AUC but delayed tmax relative to 
a control tablet.  Unlike other gastroretentive formulations, this design decouples drug 
release rate from gastric retention time and effectively retains in the stomach regardless 
of prandial state.   
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Chapter 1: Drug Delivery Applications of Poly(urethanes)1 
1.1 ABSTRACT 
Since their introduction over 50 years ago, poly(urethanes) have been applied to 
nearly every industry. This review describes applications of poly(urethanes) to the 
development of modified release drug delivery. Although drug delivery research 
leveraging poly(urethanes) has been ongoing for decades, there has been renewed and 
substantial interest in the field in recent years. The chemistry of poly(urethanes) and the 
mechanisms of drug release from sustained release dosage forms are briefly reviewed. 
Studies to assess the impact of intrinsic drug properties on release from poly(urethane)-
based formulations are considered. The impact of hydrophilic water swelling 
poly(urethanes) on drug diffusivity and release rate is discussed. The role of pore formers 
in modulating drug release rate is examined. Finally, the value of assessing mechanical 
properties of the dosage form and approaches taken in the literature are described. 
1.2 INTRODUCTION 
Poly(urethanes) are among the most ubiquitous of materials found in society, 
owing to their versatile properties.  They can be found in automobiles, chairs, beds, 
refrigerators, and many other household items [1].  Early research into the chemistry of 
poly(urethanes) can be found as early as 1947 [2].  By varying different substituents and 
their ratios, different poly(urethanes) with a wide range of physicochemical properties 
can be synthesized at large scales. 
                                                 
 
1 Published in: M.B. Lowinger, S.E. Barrett, F. Zhang, R.O. Williams, Sustained release drug delivery 
applications of polyurethanes, Pharmaceutics. 10 (2018). doi:10.3390/pharmaceutics10020055.  Michael 




This review presents an overview of recent applications of poly(urethanes) to 
sustained release drug delivery.  Previous review publications generally focused on the 
chemistry, synthesis, and properties of poly(urethanes).  Cherng et al. authored an 
extensive review of poly(urethane)-based drug delivery systems, however it was 
published over five years ago [3].  Since that time, there has been significant 
advancement in the research area of poly(urethanes), particularly as applied to parenteral 
sustained release dosage forms. 
Poly(urethanes) have been applied to drug products in nearly every conceivable 
configuration.  Seo and Na explored modifications to poly(urethane) membrane porosity 
from a non-erodible drug eluting stent [4].  Guo et al. developed biodegradable 
poly(urethane) stent coatings enabling adjustable drug release [5].  Chen et al. explored 
the use of poly(urethane) pressure-sensitive adhesives for transdermal drug delivery [6].  
Several studies have explored the controlled release of antibiotics from poly(urethane) 
matrices through tissue scaffolds [7], bone grafts [8], microspheres [9], and nanoparticles 
[10].  Temperature- and pH-responsive poly(urethane) nanoparticles have been developed 
to deliver doxorubicin to the tumor microenvironment [11].  Drug loaded poly(urethane) 
implants have been studied for the treatment of bacterial infection [12] and inflammation 
[13].  The polymers have been extensively applied in the development of intravaginal 
rings [14–25].  Poly(urethanes) have also been applied to modulate the release 
characteristics of orally administered tablets [26].   
Experimental work exploring monolithic mixtures of a polymer (ethylene vinyl 
acetate) with model drug compounds has been documented as early as 1964 [27] and the 




Both biodegradable and biostable sub-dermal implant poly(urethane) formulations have 
been of more recent interest [3]. 
1.3 CHEMISTRY OF POLY(URETHANES)  
Poly(urethanes) are a group of condensation polymers that include the urethane (‒
NHCOO‒) group in the chemical structure (Figure 1.1).  They are typically synthesized 
by a step-growth polymerization reaction between isocyanates and polyols in the 
presence of a suitable catalyst.  Poly(urethanes) synthesized solely from isocyanates and 
polyols generally have poor mechanical properties.  Therefore, chain extenders are added 
to the structure in order to induce microphase separation between the two 
thermodynamically incompatible segments.  The two segments are commonly described 
as hard segments (composed of the isocyanate and chain extender components) and soft 
segments (composed of the polyol component).  The hard segments impart mechanical 
strength, whereas the soft domains provide flexibility (Figure 1.1). 
 
 





Diisocyanates are commonly employed in the synthesis of poly(urethanes), which 
can be divided into aliphatic and aromatic diisocyanates.  In general, aromatic 
diisocyanates are more reactive than aliphatic species.  For example, poly(urethanes) 
made from aliphatic diisocyanates demonstrated more resistance to ultraviolet radiation, 
whereas those made from aromatic diisocyanates have been shown to undergo 
photodegradation [35,36].  Poly(urethanes) based on aromatic diisocyanates have also 
been shown to exhibit less biocompatibility than those synthesized from aliphatic 
diisocyanates, caused by toxic degradation products.  Poly(urethanes) prepared with 
toluene diisocyanate have been shown to degrade under physiological conditions to yield 
2,4-toluene diamine, which has known toxicity [37].  Kääriä et al. conducted an in vivo 
study using a poly(urethane) prepared from the aromatic 4,4’-methylenediphenyl 
diisocyanate and observed cytotoxicity attributed to the aromatic amine 4,4’-
methylenedianiline produced as a degradation product of the polymer [38]. 
1.3.3 Chain Extenders 
Chain extenders are typically low molecular weight (<400 Da) bisamines or diols, 
such as 1,4-butandiol, 1,3-propanediol, and ethylene diamine.  The physical and 
mechanical properties of poly(urethanes), including hardness and crystallinity, are 
dependent on the extent of phase separation between the hard and soft segments.  The 
extent of phase separation is, in part, a function of the type and number of chain 
extenders used for polymerization.  Jabbari and Khakpour investigated the impact of 
changes to the mole fraction of poly(urethane) chain extruder to the porosity of prepared 
microspheres [39].  They observed that the pores in poly(urethane) microspheres 




increased the chain extruder content to 67 mol%, the polymer stiffness increased and 
formation of pores was inhibited. 
1.3.4 Polyols 
Polyols are generally di-hydroxyl terminated macroglycols of poly(esters), 
poly(ethers), and poly(carbonates) in the molecular weight range of 1000 to 5000 Da.  
The molecular weight and type of polyol plays a significant role in the physicochemical 
and mechanical properties of the poly(urethane).  Poly(ester)-based poly(urethanes) often 
have good mechanical strength and thermal stability, however they are susceptible to 
hydrolysis [40].  Biodegradable poly(ester urethanes) have been prepared from lysine 
diisocyanate with D,L-lactide, ε-caprolactone, and other monomers [41].  Kaur et al. 
developed a biodegradable intravaginal ring composed of a poly(ester urethane) prepared 
from bis(4-isocynaatocyclohexyl)methane with poly(tetramethylene ether)glycol and ε-
caprolactone which released the antiretroviral dapivirine at target levels for one month 
[42].  Yu et al. developed biodegradable poly(urethanes) based on L-phenylalanine that 
possess tunable mechanical properties and degradation rates over a wider range than was 
achievable with poly(lactic acid) [43]. 
Poly(ether)-based poly(urethanes) tend to be more hydrolytically stable and 
exhibit more elasticity at lower temperatures.  However, they can be more susceptible to 
oxidative and thermal lability [44,45].  It was found that poly(ether urethane) used as 
pacemaker lead insulation suffered from stress cracking due to oxidation after being 
placed in humans for long periods of time [46].  However, antioxidants have been used to 
stabilize poly(ether urethanes) to prevent oxidation and prolong the life of the polymer 




polyethylene oxide (PEO).  PEO-based poly(urethanes) exhibit sensitivity to water due to 
the hydrophilicity and water-absorbing capacity of the ethylene oxide units [3].  Ikeda et 
al. demonstrated that the larger the PEO content, the higher the degree of swelling which 
increased the drug release rate of slowly releasing model compounds [48]. 
Poly(carbonate)-based poly(urethanes) were developed in response to the 
disadvantages of poly(ester) and poly(ether) based poly(urethanes).  They exhibit good 
mechanical properties, heat stability, and hydrolytic stability, but they have been shown 
to undergo enzymatic hydrolysis and oxidative degradation by inflammatory cells in 
long-term in vivo studies [49].   
1.3.5 Synthesis 
Poly(urethanes) are generally synthesized by reacting the isocyanate, polyol, and 
chain extender together at temperatures above 80°C [50].  The central reaction is the 
formation of a urethane linkage that occurs when an isocyanate reacts with an alcohol 
group of the polyol.  The exothermic polymerization reaction is generally carried out in 
one of two ways.  The “one-shot method” involves mixing all of the ingredients together, 
while the “prepolymer method” features the reaction of the polyol with an excess of 
isocyanate, followed by a subsequent reaction with the chain extender to form a linear 
block copolymer with alternating blocks of hard segment and soft segment [29].  The 
prepolymer method has been shown to yield more ordered structure with better control of 
polymer properties [51]. 
Two manufacturing methods are typically employed for industrial production: the 
belt process and the reaction extruder process.  During the belt process, all components 




onto a belt, where it solidifies.  The solid material is then granulated and may be blended 
with other components and extruded into pellets.  Utilization of a reaction extruder allows 
for the mixing of prepolymers or all components inside of the extruder, where screw 
design and temperature can be modified to suit the desired product properties.  The 
urethane reaction is nearly complete by the time the material exits the extruder and 
uniform pellets may be formed by the use of underwater or strand pelletizers [50]. 
Since phase separation of poly(urethanes) is dependent on the temperature and 
shear conditions during polymerization, the process may have a significant influence on 
the product properties.  Consequently, although two poly(urethane) batches may start 
from the same raw materials, their physical properties can be very different [50]. 
1.4 DRUG RELEASE MECHANISMS 
Solute diffusion, polymer swelling, and polymer erosion or degradation are 
generally considered to be the main driving forces for drug transport from a polymeric 
matrix [52].  However, other phenomena may be involved in the control of drug release 
and are discussed in more detail  in other publications [53]. 
1.4.1 Solute Diffusion 
Fick’s law of diffusion is the fundamental basis for the mechanism describing 
drug transport from a polymer matrix.  Fickian diffusion refers to a solute transport 
process in which the polymer relaxation time is much greater than the solvent diffusion 
time.  When polymer swelling occurs, changes to diffusivity with time result in non-
Fickian drug release.  Drug release from poly(urethane) formulations can be categorized 
into two groups: (i) monolithic systems, where drug is dissolved or dispersed in a 




rate controlling membrane [53].  Table 1.1 describes the categories of solute diffusion 
from poly(urethane)-based sustained release dosage forms. 
In each of those categories, drug release kinetics will be dependent on whether the 
drug concentration is above or below its solubility in the system.  In the case of a 
reservoir system where the initial drug concentration is below its solubility, those drug 
molecules that diffuse out of the system will not be replaced by undissolved drug and the 
drug activity at the rate controlling membrane’s surface decreases with time, resulting in 
first order release kinetics.  Models have also been developed which describe first order 
release kinetics from a cylindrical intravaginal ring [54,55].   However, a reservoir 
system where the drug concentration exceeds its solubility will feature a saturated 
solution at the membrane surface, resulting in zero order release kinetics.  Over time, 
drug release kinetics from such a system will approach those of a dosage form with drug 
concentration below its solubility in the polymer [56]. 
In the case of monolithic systems, the device geometry and drug loading will 
significantly affect the drug release kinetics.  For a monolithic system where the initial 
drug concentration is below its solubility in the system, models have been derived to 
describe the drug release of thin films, spheres, and cylinders, many of which assume an 
exponential function of release rate with time [57,58].    In the case of a monolithic 
dispersion where the drug is above its solubility in the system, Higuchi described a 
square root of time relationship between the amount of drug released from a thin film 






Table 1.1: Categories of Solute Diffusion from Poly(urethane)-based Sustained Release 
Dosage Forms.   
Dosage Form 
Type 
Drug Concentration in 
Polymer 
Release Kinetics Examples 
Monolithic 
Cdrug ≤ Csolubility 
Geometry and drug load 
dependent 
[57,58] 
Cdrug > Csolubility 




Cdrug ≤ Csolubility First order [54,55] 
Cdrug > Csolubility Zero order [56] 
 
1.4.2 Polymer Swelling 
Depending on the polyol used, poly(urethanes) may exhibit substantial polymer 
swelling which can impact drug release kinetics in several ways.  When a polymer swells, 
the length of the diffusion pathways increases.  This can result in decreasing drug 
concentration gradients, which may decrease drug release rates.  Guo et al. observed that 
the swelling of a synthesized poly(urethane) matrix slowed down the drug release rate, 
which was attributed to increased diffusion length [5].   
Polymer swelling also increases the mobility of the polymer chains, which 
increases drug mobility and, potentially, increases drug release rates.  Once a water 
content specific to each polymer is reached, the polymer mobility steeply increases in a 
phenomenon called “polymer chain relaxation” or “glassy-to-rubbery phase transition” 
[53].  However, poly(urethanes) commonly employed for pharmaceutical applications 
exhibit glass transition temperatures below room temperature, so the transition of 




significance to drug release [60].  Clark et al. applied similar pseudo-steady state 
approach as Higuchi’s diffusion model to effectively predict the release of tenofovir from 
an intravaginal ring composed of hydrophilic poly(urethane) [54].  They argued that 
polymer swelling had minimal impact on the long-term drug release kinetics since the 
polymers reach equilibrium swelling at early time points and it was thus unnecessary to 
account for it in the model. 
Beyond polymer chain mobility itself, water swelling increases free volume for 
diffusion, thereby increasing diffusivity of drugs [61].  Dapivirine, when released from an 
intravaginal ring composed of a water-swelling poly(urethane) grade, exhibited faster 
release than from a ring composed of non-swelling poly(urethane) (Figure 1.2) [14].  
Given the wide variety of PEO-based poly(urethanes) available commercially, polymer 
swelling has the potential to dramatically impact drug release kinetics from dosage forms. 
 
 
Figure 1.2: Cumulative flux (Q) of dapivirine as a function of time from a water swelling 
(WS-PU) and non-water swelling (NWS-PU) poly(urethane) matrix.  ** denotes wt% 
cumulative release of dapivirine over 30 days.  Adapted from reference [14], Elsevier, 




1.4.3 Polymer Erosion and Degradation 
The erosion and degradation of polymers to facilitate drug release are often 
confounded; however, they will be separated for the purpose of this review.  Goepferich 
and Langer differentiated the two processes by defining degradation as involving 
cleavage of polymer chains into oligomers and monomers, while erosion can be defined 
as a general loss of weight from the polymer [62].  Consequently, although degradation 
of water-insoluble polymers is a step in its erosion process, the degradation of the 
polymer itself is not erosion.   
Langer and Peppas defined two extremes of erosion: heterogeneous and 
homogeneous [63].  Heterogeneous erosion describes a physical situation where water 
penetration into the polymer is slow relative to polymer degradation rate.  Under this 
scenario, polymer degradation is restricted to the outermost layers and erosion 
predominantly occurs at the surface of the dosage form.  In the case of homogeneous 
erosion, water penetration occurs rapidly, degradation occurs throughout the device, and 
bulk erosion follows.  Although all bioerodible polymers are likely to undergo some 
combination of the two extremes, surface erosion may be most often observed with 
hydrophobic poly(urethanes) and those with highly reactive bonds in their backbone 
structure, whereas hydrophilic poly(urethanes) and those with less reactive ester linkages 
are more likely to undergo bulk erosion [53].  Additionally, the water penetration rate 
may vary depending on the geometry of the delivery system [64].   
Hafeman et al. synthesized hydrophilic poly(ester)-based poly(urethanes) from ε-
caprolactone and observed rapid swelling followed by bulk erosion with approximately 
50-80% mass remaining after 36 weeks [65] (Figure 1.3).  In a subsequent study 




authors found that the hydrophilic drug released from the poly(urethane) scaffold over the 
course of approximately 30 days.  Given the difference in time scales between the drug 
release and polymer degradation rates, the investigators concluded that tobramycin 
release was independent of polymer degradation [66].  The study demonstrates the ability 
to develop biodegradable sustained release dosage forms in which drug release kinetics 
are not dependent on polymer degradation kinetics. 
 
 
Figure 1.3: In vitro degradation of poly(urethane) scaffolds.  By 36 weeks, polymers from 
prepared from lysine triisocyanate (LTI) had completely degraded, while the 
poly(urethanes) prepared from hexamethylene diisocyanate trimer remained at 52-81% of 





1.5 APPROACHES TO MODULATE DRUG RELEASE KINETICS 
Hombreiro-Pérez et al. described the key mass transport phenomena governing 
drug release through a polymer, including drug dissolution in the polymer; drug diffusion 
through the polymer matrix and/or through water-filled pores; drug diffusion through the 
unstirred liquid boundary layer on the surface of the dosage form; and diffusional and 
convective transport within the release medium [67].  Through deliberate polymer and 
formulation selection, the release kinetics of a particular drug may be modulated to 
achieve a target dose.  Table 1.2 summarizes the approaches that may be taken to 
modulate drug release kinetics from a poly(urethane)-based reservoir sustained release 
dosage form. 
Table 1.2: Approaches to Modulate Drug Release Kinetics from a Poly(urethane)-based 
Reservoir Sustained Release Dosage Form. 
Driver Approach Examples 
Drug Solubility 
in Polymer 





Polymer selection to increase or reduce polymer 
crystallinity 
[68–70] 
Polymer selection to increase or reduce polymer 
molecular weight 
[71,72] 
Polymer selection to increase or reduce soft segment to 





Polymer selection to increase or reduce soft segment to 
hard segment ratio 
[73,74] 





1.5.2 Intrinsic Drivers of Drug Release Through a Polymer 
1.5.2.1 Drug Solubility in Polymer 
In matrix systems where the drug is above its percolation threshold, it is 
conceivable for drug release to occur by diffusion through drug-rich channels [27,78].  
However, for matrix systems where drug load is below its percolation threshold and for 
all reservoir systems, drug must first dissolve in the polymer in order to diffuse through 
it.  For those formulations, drug solubility in the polymer is an important phenomenon.  
Johnson et al. found that release of hydrophilic tenofovir with a calculated logP of -2.3 
was barely detectable from the hydrophobic poly(urethane) Tecoflex EG-85A, attributed 
to poor solubility in the polymer [14].  However, dapivirine with a calculated logP of 6.3 
exhibited near zero order release from a similarly hydrophobic poly(urethane) Tecoflex 
EG-80A [19].  Van Laarhoven et al. measured the solubility of etonogestrel and ethinyl 
estradiol in ethylene vinyl acetate copolymers and found that the two hydrophobic drugs 
were sufficiently soluble in the hydrophobic polymer that they were present in the 
finished product in a molecularly dissolved state [56].  Clark et al. determined the 
solubility of tenofovir in a hydrophilic poly(urethane) and observed that its solubility was 
100 to 1000 times lower than the drug loading explored in their studies [54]. 
1.5.2.2 Drug Diffusivity Through Polymer 
The phase state of the polymer has been shown to impact diffusivity of drug 
through it.  Almeida et al. studied the impact of vinyl acetate content on the release rate 
of metoprolol tartrate from melt extruded ethylene vinyl acetate matrices in the presence 
of varying levels of poly(ethylene) oxide.  Lower vinyl acetate content results in greater 




content polymers exhibited slower drug release rates than those extruded with higher 
vinyl acetate content polymers.  By fitting the experimental data to an analytical model of 
Fick’s second law of diffusion, they were able to show that release rate differences 
between polymers could be explained by changes to the apparent diffusion coefficient 
(Figure 1.4) [68].  Tallury et al. explored the impact of ethylene vinyl acetate copolymer 
composition on the release of chlorhexidine and acyclovir from polymer matrices.  They 
observed a strong relationship between vinyl acetate content and drug release for both 
systems, where higher vinyl acetate content exhibited faster drug release [69].  Although 
the effect of polymer crystallinity on drug release from nonerodible poly(urethane)-based 
dosage forms has not been extensively studied, several investigators correlated the 
crystallinity of the soft segment to degradation rate of poly(ester urethanes).  Reddy et al. 
proposed that higher crystallinity of the poly(caprolactone) soft segment   resulted in 
reduced polymer degradation rates, which slowed the release of the model drug 
theophylline [70].   
The molecular weight of the polymer may also impact the diffusion of drug 
through the dosage form.  Hsu and Langer investigated the impact of changes to ethylene 
vinyl acetate molecular weight on the release rate of bovine serum albumin (BSA).  They 
observed a substantial decrease in BSA release rate with relatively small increases in 
ethylene vinyl acetate molecular weight [71].  Skarja and Woodhouse investigated the 
effect of molecular weight on the properties of poly(urethanes) composed of either 
poly(caprolactone) or poly(ethylene oxide) as the soft segment.  They found that phase 
separation between the hard and soft segments and crystallinity of the soft segment 
increases with soft segment molecular weight.  For poly(urethanes) based on hydrophobic 




weight polymer, however those based on hydrophilic poly(ethylene oxide) might be 
expected to release drug at faster rates [72]. 
 
 
Figure 1.4: (A) Theory (curves) and experiments (symbols): metoprolol tartrate release 
from EVA 28-based matrices containing 0% PEO 7M (), 5% PEO 7 M (), or 5% PEG 
7M/Lutrol (9/1, w/w) ().  (B) Apparent diffusion coefficients of metoprolol tartrate in 
EVA-based matrices, containing 0% PEO 7M, 5% PEO 7M, or 5% PEO 7M/Lutrol (9/1, 
w/w).  Adapted from reference [68], Elsevier, 2012 with permission. 
For poly(urethanes), the ratio between soft segment and hard segment has also 




segment to hard segment ratio on the release of ciprofloxacin.  The poly(urethane)-urea 
elastomers were synthesized from the aromatic toluene diisocyanate and the hydrophilic 
poly(ethylene glycol).  As soft segment to hard segment ratio was decreased, the 
investigators observed a decrease in ciprofloxacin release rate from drug/polymer films.  
The authors attributed the slower drug release to increased cross-linking of the hard 
segments in polymers featuring a higher concentration of hard segment.  They speculated 
that increased cross-linking would reduce water penetration into the matrix and drug 
diffusion out of the matrix [73].   
Verstraete et al. investigated the impact of soft segment to hard segment ratio on 
the release rates of diprophylline, theophylline, and acetaminophen for hydrophilic 
thermoplastic poly(urethanes) for which the soft segment is composed of poly(ethylene 
oxide).  As the soft segment to hard segment ratio increased, the fraction of poly(ethylene 
oxide) in the polymer structure increased.  The authors observed an increase in swelling 
for the polymers Tecophilic SP60D60, SP93A100, and TG2000 ranging from 60% to 
900% weight gain.  When investigating the drug release kinetics of the three drug 
compounds from matrices of each polymer, they found that all drugs followed the same 
trend with the TG2000-based matrix releasing fastest and the SP60D60-based matrix 
releasing slowest (Figure 1.5) [74].  Increased water uptake and faster drug release may 







Figure 1.5: Influence of length of the poly(urethane) soft segment (polyethylene oxide) 
on the in vitro release kinetics of drugs with different aqueous solubility (acetaminophen, 
diprophylline, and theophylline) from poly(urethane)-based matrices (SP60D60, 




1.5.3 The Use of Pore Formers 
The incorporation of soluble components to an otherwise poorly soluble barrier 
has been utilized as an approach to modulate the release of drugs through film coated 
tablets for decades [79–83].  A similar approach has been applied to the development of 
drug/poly(urethane) dosage forms in order to optimize the drug release rate.  Kim et al. 
evaluated the effect of poly(ethylene glycol), D-mannitol, and bovine serum albumin on 
the release of the antibiotic cefadroxil from a poly(urethane) matrix [75].  They observed 
that matrices utilizing bovine serum albumin as the pore former exhibited the fastest drug 
release.  The authors proposed that immiscibility of the pore former with the 
poly(urethane) could facilitate channel formation and thus increase drug release rate.   
Donelli et al. investigated the utility of incorporating poly(ethylene glycol) and 
bovine serum albumin into a poly(urethane) matrix to modify the release rate of the 
antifungal drug fluconazole [76].  They found that matrices incorporating poly(ethylene 
glycol) exhibited increased drug release relative to a control without pore former, 
whereas matrices incorporating bovine serum albumin exhibited sustained drug release 
relative to the control.  Sreenivasan observed an increased release rate of the anti-
inflammatory drug hydrocortisone when adding methyl β-cyclodextrin to poly(urethane) 
[77].  Claeys et al. explored the impact of poly(ethylene glycol), polysorbate 80, and the 
dicarboxylic acids malonic, succinic, maleic, and glutaric acid on the release of 






Figure 1.6: Mean dissolution profiles (± SD) of polyester-based poly(urethane) 
(Pearlbond) matrices as a function of (A) drug load: 50% (), 60% (), and 65% () 
metoprolol tartrate; (B) drug solubility: 65 wt% theophylline (), diprophylline (), and 
metoprolol tartrate (); pore former (C) PEG 4000 or (D) Polysorbate 80; 65 wt% 
diprophylline with 0% (), 2% (), 5% (), and 10% () of pore former, respectively.  
Adapted from reference [60], Elsevier, 2015 with permission. 
 
1.6 MECHANICAL PROPERTIES OF POLY(URETHANE)-BASED DOSAGE FORMS 
Since many poly(urethane)-based sustained release dosage forms are intended to 
remain in vivo for extended periods of time, their mechanical properties are critical to 
ensure consistent drug release kinetics and good patient adherence.  The dosage forms 
must exhibit enough elasticity to deform seamlessly without causing discomfort to 
patients during routine daily activities and without causing tissue damage or 




prevent fracture, which would alter geometry and potentially affect drug release rate.  For 
example, intravaginal rings that are too soft may not be effectively retained and could be 
expelled from the vagina [85].   
1.6.1 Patient Perceptions 
Given that many of the mechanical properties are driven by patient perceptions, it 
can be difficult to determine an appropriate target for a dosage form under development.  
The target mechanical properties of each dosage form may be dependent on the route of 
administration and duration of the product.  However, patients are likely to have more 
interaction with intravaginal rings than most other parenteral formulations and therefore 
investigators have evaluated the mechanical performance of intravaginal rings more 
extensively than most other presentations.   
Morrow Guthrie et al. conducted a clinical study to understand the relationship 
between user perceptions and mechanical properties of intravaginal rings composed of 
poly(urethane) [86].  Users perceived a ring with a matte and textured surface to be easier 
to manipulate during insertion, whereas they perceived a ring with a glossy and smooth 
surface to be more slick and challenging to insert.  The study participants also expected 
rings composed of softer materials to be more comfortable to use.  Although the 
participants preferred a small diameter ring, it conflicted with their general desire for a 
more pliable dosage form.  For a given material at a defined cylinder diameter, a smaller 
diameter ring will be more difficult to squeeze.  Faced with these tradeoffs, users were 
more comfortable with using softer materials and smaller diameter cylinders, even if the 




1.6.2 Mechanical Testing of Finished Product 
Since most investigators lack the clinical data necessary to quantify patient 
preferences, studies describing the assessment of an investigational dosage form’s 
mechanical properties typically reference their findings back to a marketed product.  
Baum et al. proposed several techniques to evaluate the mechanical properties of an 
experimental silicone-based intravaginal ring, comparing it to the commercially available 
Estring® [87].  The tensile strength, elongation, and compression strength were 
determined using methods adapted from ASTM D2240 and ISO 8009 standards [88,89].  
Verstraete et al. built on Baum’s efforts by applying those techniques to 
poly(urethane)-based intravaginal dosage forms and comparing back to the marketed 
product Nuvaring® [15].  Shore durometer hardness was measured using an indentation 
test on the surface of the ring.  Elongation and force at maximum extension were 
measured using an extension testing system.  To evaluate elongation, a sample was fixed 
between two hooks and its axial length was measured after applying a defined force.  In 
order to assess maximum elongation, the sample was stretched at a defined rate until 
breakage.  The researchers sought to evaluate resistance to compression by subjecting a 
sample to repeated compression cycles at a defined speed and amplitude and assessing 
changes to the diameter along the axis of compression and orthogonal to it.  Table 1.3 
provides a summary of the measured intravaginal ring mechanical properties in 
comparison to the marketed product.  By performing a variety of compression, 
elongation, and indentation tests, the investigators were able to assess the mechanical 






Table 1.3: Overview of intravaginal ring properties (mean ± SD, n = 3).  Devices that 
featured similar mechanical properties to reference were highlighted in grey.  Adapted 




















72 ± 3 82.8 ± 13.7 587.9 ± 117.4 94.6 104.6 
50/50 
metronidazole/SP-93-100 





51 ± 1 49.7 ± 12.4 517.0 ± 4.9 98.0 101.7 
20/80  
Lactic Acid/EG-85A 
62 ± 2 68.6 ± 22.7 389.4 ± 34.3 98.2 101.3 
20/80  
Lactic Acid/EG-93A 
71 ± 2 87.7 ± 8.15 336.7 ± 24.9 96.0 103.8 
20/80  
Lactic Acid/EG-100A 
80 ± 2 98.6 ± 11.6 244.6 ± 37.4 94.3 105.1 
20/80  
Lactic Acid/EG-60D 
80 ± 4 105.4 ± 13.8 173.8 ± 22.2 93.7 107.2 
20/80  
Lactic Acid/EG-72D 
86.3 ± 3 129.3 ± 14.1 125.7 ± 13.9 89.5 110.0 
a Hardness and maximum load should be similar to the NuvaringTM reference values. 
b Mean elongation at break should not be less than 300%. 
c After compression experiments, the diameter along the axis of compression (OD1’) and 
the diameter orthogonal to the axis of compression (OD2’) should be at least 90% of their 
initial values. 
 
Clark et al. performed a destructive extension test on their segmented intravaginal 
ring samples both before and after 31 day in vitro release testing.  Samples were stretched 




were recorded [90].  The investigators did not compare measured properties back to a 
marketed product.  Without a benchmark, it can be difficult to interpret the outcome as to 
whether the failure conditions were beyond what is reasonably expected during normal 
handling.   
Young’s modulus measures a material’s resistance to being deformed elastically 
when a stress is applied to it.  A stiffer material will have a higher Young’s modulus.  
Ugaonkar et al. leveraged the Young’s modulus as a measure of flexibility by subjecting 
a 25 mm long cylindrical segment to a defined elongation at a specified rate and again 
compared the measured value for their experimental dosage form to that of the marketed 
product Nuvaring® [55].  Clark et al. developed a model to predict the force necessary to 
compress an intravaginal ring material a given distance based on the Young’s modulus 
[54].  Although Young’s modulus is an effective measure of stiffness, it does not provide 
information on elongation and compression properties. 
Crnich et al. were interested in understanding the effect of ethanol exposure on 
the mechanical properties of poly(urethane) stents.  They performed tensile strength 
testing, including force-at-break, failure stress, elongation at failure, maximum strain, and 
modulus of elasticity in accordance with ISO standard 10555-1 [91].  The investigators 
concluded that exposure to ethanol had a minimal effect on the mechanical properties of 
poly(urethane) catheters. 
Johnson et al. performed a tensile strength test on their intravaginal ring samples 
in a similar fashion to others [14].  Rings were stretched to a defined force at a specific 
rate and any evidence of failure or changes to diameter were assessed.  The investigators 
also performed compression/retraction force tests in which the rings were compressed at 




experiment (Figure 1.7).  They benchmarked to a marketed product and observed that 
their hydrophilic poly(urethane)-based intravaginal ring exhibited similar mechanical 
properties to the Nuvaring® reference (“EVA-R”) when kept dry.  However, the hydrated 
poly(urethane)-based ring exhibited faster recoil than the reference, which the authors 
pointed out could improve retention in the vaginal tract. 
 
 
Figure 1.7: Force versus percent ring compression for experimental (segmented IVR) and 
Nuvaring® (EVA-R) intravaginal rings.  Equilibrium swelling, as determined by mass 
change, was achieved after 3 days in water.  Each ring was brought to 50% compression 
and subsequently allowed to recover to its original diameter as indicated by the direction 
of arrows.  Adapted from reference [14], Elsevier, 2010 with permission. 
1.6.3 Gamma Irradiation 
Gamma irradiation is an established approach to sterilize materials for biomedical 
application.  However, polymer irradiation may result in crosslinking or chain scission, 
resulting in physical and mechanical changes to the polymer.  It has been generally 
reported that medical poly(urethane) products are able to withstand multiple exposures to 
gamma irradiation without change to physical or mechanical properties [92].  For 




properties of an aromatic poly(ether urethane urea) and an aliphatic poly(carbonate)-
based poly(urethane) [93].  The investigators assessed tensile properties with uniaxial 
stress-strain data following ASTM D638 methods and elongation properties using a stress 
hysteresis test.  Although they observed a change in molecular weight distribution and 
soft segment glass transition temperature for both polymers, they found no significant 
effect of irradiation on the tensile properties and a small increase in hysteresis stress 
values. 
In a separate study, Simmons et al. examined the effect of gamma irradiation on 
the mechanical properties of an aromatic poly(ether urethane) and an aromatic 
poly(urethane) based on both poly(ether) and poly(siloxane) in the soft segment [94].  
They determined the ultimate tensile strength, ultimate elongation, and Young’s modulus 
prior to and following sterilization.  Gamma irradiation appeared to stiffen the 
poly(ether)/poly(siloxane)-based material, with an approximate 20% increase in Young’s 
modulus, while tensile strength and elongation remained largely unchanged.  There was 
no significant effect of irradiation on the measured mechanical properties of the 
poly(ether)-based poly(urethane). 
Gorna et al. noted that previous studies had focused on the impact of gamma 
irradiation on the properties of non-erodible poly(urethanes).  Therefore, they 
investigated the effect of gamma irradiation on the mechanical properties of 
biodegradable poly(urethanes) based on poly(ethylene oxide) and poly(-caprolactone), 
used for medical implants and scaffolds [95].  They measured the tensile strength, 
Young’s modulus, and elongation at break before and after gamma irradiation.  The 




with the poly(urethane) based on poly(ethylene oxide) exhibiting a substantial 50% 
decrease in tensile strength. 
However, Ahmed et al. studied the effect of gamma irradiation on the mechanical 
properties of a non-erodible aromatic poly(carbonate urea) based poly(urethane) 
alongside a biodegradable aliphatic poly(caprolactone) based poly(urethane) [96].  They 
observed an approximate 25% decrease in Young’s modulus and ultimate tensile strength 
for both polymers following irradiation.  Consequently, no generalized conclusions can 
be made with regard to the effect of gamma irradiation on the mechanical properties of 
varying types of poly(urethanes), underscoring the importance of verifying mechanical 
properties of the drug product during development. 
1.7 CONCLUSION 
Owing to their chemical diversity, poly(urethanes) can be tailored to exhibit a 
wide variety of physical properties.  Crystallinity, hydrophilicity, hydrated porosity, 
mechanical strength, and bioerodibility can be tuned to achieve the desired dosage form 
characteristics and release rate for a diverse array of treatment duration and route of 
administration.  The diversity of poly(urethane) chemistry suggests that one may have 
substantially more degrees of freedom to select a polymer exhibiting good or poor drug 
solubility than with silicone or poly(ethylene-co-vinyl acetate) elastomers.  The ability to 
tune the extent of water swelling by changing the soft segment to hard segment ratio of 
poly(urethanes) presents an exciting route to modulate drug release kinetics independent 
of drug solubility in polymer.  Despite the available opportunities, few commercialized 
drug products leverage poly(urethanes), suggesting that it remains a nascent field with 




based parenteral sustained release dosage forms are well suited toward therapies where 
high adherence to a consistent dose over a long duration is critical, particularly infectious 
and neurodegenerative diseases. 
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Chapter 2: Can Drug Release Rate from Implants Be Tailored Using 
Poly(urethane) Mixtures?2 
2.1 ABSTRACT 
Hydrophobic and hydrophilic thermoplastic poly(urethane) (TPU) mixtures offer 
the opportunity to tune water swelling capacity and diffusion rate for drugs exhibiting 
broadly different properties. We sought to (1) assess the range of drug diffusion rates 
achieved by varying hydrophilic-to-hydrophobic TPU ratio relative to varying ethylene 
vinyl acetate (EVA) crystallinity; (2) investigate the effect of mixture ratio on 
permeability of emtricitabine; and (3) investigate the impact of the extrusion process on 
mixing of the two TPUs and the resulting impact on drug diffusion. The permeability of 
water-soluble emtricitabine exhibited a 736-fold range across the blends of TPU, but only 
a 3.4-fold range across the EVA grades investigated. Varying hydrophilic content of the 
TPU mixture from 0% to 25% (w/w) led to a negligible permeability change, while 
changing hydrophilic content from 55% to 100% resulted in a linear 3-fold increase in 
drug permeability. Interestingly, an 123-fold permeability change occurred between 50% 
and 55% hydrophilic polymer. Extrusion process parameters exhibited minimal impact 
on homogeneity and drug diffusion. These findings suggest that hydrophilic polymer 
domains form a continuous network at levels above 55% hydrophilic TPU, thus 
facilitating a water-filled porous network when exposed to water that provides a 
mechanism for accelerated drug diffusion. 
                                                 
 
2 Published in: M.B. Lowinger, Y. Su, X. Lu, R.O. Williams, F. Zhang, Can drug release rate from 
implants be tailored using poly(urethane) mixtures?, Int. J. Pharm. 557 (2019) 390–401. 
doi:10.1016/j.ijpharm.2018.11.067.  Michael Lowinger designed, executed, and performed the 





Patient adherence, or the extent to which patients follow the recommendations of 
their healthcare providers, has a substantial impact on health outcomes [1]. A meta-
analysis of 85 reports with electronic adherence monitoring across a variety of 
therapeutic areas found an overall rate of adherence of 71%, with some studies as low as 
34% [2]. Poor adherence to therapy can reduce the real-world efficacy of treatments. 
Nachega et al. identified a strong correlation between adherence to a class of human 
immunodeficiency virus (HIV) antiretrovirals and suppression of the virus [3]. Although 
the well-established heuristic that “drugs don’t work in patients who don’t take them” 
applies to all therapeutic areas, infectious disease patients are at particular risk. For 
example, those individuals infected with human immunodeficiency virus (HIV) who 
exhibit poor adherence to therapy may inadvertently encourage the proliferation of 
mutant variants that are resistant to the medication [4]. Consequently, significant effort 
has been spent in recent years focused on products intended to improve adherence to HIV 
therapy [5–10]. 
Among other interventions, decreasing the frequency of administration is an 
effective way to improve patient adherence [2]. Development scientists have increased 
duration of treatment by increasing drug half-life [11], designing novel oral sustained 
release formulations [12], and developing subcutaneous or intramuscular injections 
[13,14]. Although these approaches have been successful at enhancing treatment 
duration, they are limited to once quarterly administration. Intravaginal rings and 
subdermal implants have been demonstrated to decrease administration frequency to as 




potential to substantially improve patient adherence by mitigating the burden to take 
medication daily or more frequently. 
Implants may be designed as a reservoir system, with a core composed of drug 
and polymer surrounded by a rate-controlling membrane. Drug release rate from reservoir 
systems is much less driven by drug load and dosage form geometry, compared with 
matrix systems composed of a drug and polymer mixture with no membrane. 
Consequently, reservoir systems are able to decouple drug release rate and treatment 
duration, facilitating longer acting formulations [17]. Because the membrane determines 
release rate, the composition of the core may be selected in a manner that is largely 
independent from release kinetics considerations. We speculate that, to some extent, 
reservoir systems also decouple release rate from the mechanical properties of the dosage 
form in contrast to matrix systems. 
The vast majority of marketed implants and vaginal rings are composed of either 
silicone or ethylene vinyl acetate copolymer (EVA), with EVA playing a particularly 
prominent role as the rate controlling membrane polymer.  NuvaRing® is an intravaginal 
ring inserted once monthly, composed of EVA and intended to release etonogestrel and 
ethinylestradiol for contraception [18]. Nexplanon® is a subdermal implant consisting of 
a single rod administered once every 3 years, composed of EVA and intended to release 
etonogestrel for contraception [19]. Probuphine® is a subdermal implant consisting of 4 
rods administered once every 6 months, composed of EVA and intended to release 
buprenorphine for opioid dependence [20]. NuvaRing® and Nexplanon® are reservoir 
systems with an EVA polymer membrane surrounding a core. In those cases, the drug 
diffusion rate through the EVA polymer is strongly influenced by varying the vinyl 




molecule, lower vinyl acetate content of the EVA copolymer results in greater polymer 
crystallinity and slower drug diffusion [21,22]. 
Although EVA has been used in multiple commercial products with established 
biocompatibility and suitability to extrusion processing due to its shear-thinning 
thermoplastic behavior, it has several disadvantages [23]. Firstly, a relatively narrow 
range of vinyl acetate content is achievable that retains mechanical properties suitable for 
a long-term implant product, thereby limiting the ability to tune drug release rate. 
Additionally, the inherent nature of crystallinity in a polymer is variable, dependent on 
the crystallization conditions, storage conditions, and precise composition of a given 
polymer chain [24]. Moreover, polymer crystallinity can be difficult to accurately 
measure [25].  Finally, drug solubility in the polymer is a critical factor of diffusion 
through the membrane [26]. It may be expected that hydrophilic drugs with poor polymer 
solubility would have limited drug release rate, regardless of EVA crystallinity [27]. 
Moreover, it is possible that the drug diffusion necessary for release could also occur 
over time on the shelf, resulting in burst release at early time points for products that have 
sat on the shelf over long time periods. Probuphine® implants are washed to remove 
surface buprenorphine to reduce the initial burst [28,29]. 
Thermoplastic poly(urethanes) (TPU; poly(urethanes)) have been used for 
parenteral administration of medical devices with good demonstrated biocompatibility 
[30–32]. Poly(urethane) chemistry has been extensively covered in prior publications 
[26,33,34]. Hydrophilic poly(urethanes), in which the soft segment is polyethylene oxide 
(PEO), have been demonstrated to swell when immersed in water in proportion to the 
ratio of soft segment in the polymer [35]. Drug release rate through these TPU polymers 




The extent of hydrophilicity of the TPUs presents an opportunity to define an 
appropriate drug release profile. In contrast to the relatively narrow range of vinyl acetate 
content practically achievable to tune drug release, hydrophilic TPUs have been 
synthesized covering a wide range of swelling extent [35]. The extent of water swelling is 
also easily measured, in contrast to polymer crystallinity, allowing for good quality 
control. Finally, diffusion through water-filled pores is likely to be the major drug release 
pathway, making drug solubility in the non-swollen polymer a substantially less relevant 
parameter governing release kinetics [37]. 
The ability to tune the water-swelling properties of poly(urethanes) as the rate 
controlling membrane polymer provides an opportunity to modulate release rate 
independent of drug solubility in the non-swollen membrane polymer. Johnson et al. 
described findings of a prototype intravaginal ring composed of hydrophilic TPU tubing 
filled with a semisolid paste of tenofovir (a hydrophilic drug), glycerol, and water [27].  
The mechanism of drug release through the membrane polymer was proposed to be the 
creation of a pore structure driven by swelling upon contact with water. Notably, the in 
vitro release data showed no measurable burst effect and a zero-order release rate 
determined by their relative propensity to uptake water. A subsequent publication by 
Clark et al. detailed their effort to develop a single intravaginal ring capable of delivering 
tenofovir (a hydrophilic drug) and levonogestrel (a hydrophobic drug) [38]. They noted 
that their approximately 7-log difference in their partition/distribution coefficients 
precluded release from the same polymer system. Consequently, they developed a ring 
composed of one segment containing levonogestrel surrounded by a hydrophobic, non-
swelling TPU and the other segment consisting of tenofovir surrounded by a hydrophilic, 




Drugs vary widely in physicochemical properties and dose, however there are a 
limited number of hydrophilic TPUs readily available to be used in pharmaceutical 
formulations. Blends of water insoluble polymers of varying hydrophilicity have been 
extensively leveraged to modulate drug diffusion through membranes in the tablet film 
coating and multiparticulate oral controlled release fields. Amighi and Moës investigated 
different ratios of Eudragit® RS and RL as a coating to theophylline-containing pellets 
[39]. Eudragit® RS and RL are water insoluble acrylate/methacrylate copolymers 
containing different amounts of quaternary ammonium. They demonstrated the ability to 
achieve a broad range of release rates in an approximately proportional relationship to the 
polymer mixture composition. Lecomte et al. studied ratios of ethylcellulose and 
Eudragit® L as a coating to propranolol-containing pellets [40]. Ethylcellulose is 
insoluble in water, while Eudragit® L is an anionic poly(methacrylate) soluble in 
aqueous media at pH > 6. The investigators were able to modulate the drug release 
kinetics in approximate proportion to the polymer mixture composition. Consequently, 
we expect that mixtures of a hydrophobic and hydrophilic TPU in different ratios will 
allow us to broadly tune the diffusion rate of a model hydrophilic drug through a 
membrane as a function of membrane composition. 
We hypothesize that using mixtures of hydrophilic and hydrophobic TPUs as the 
rate controlling membrane polymer allows for a wider range of release rates for a 
hydrophilic drug than varying the vinyl acetate content of EVA. This approach has not 
been extensively studied in the literature and offers the opportunity to mitigate the effect 
of drug/polymer interactions on drug release rate. Several patents and patent applications 
have described the use of TPU blends and found that there was a change in diffusion rate 




rate can be broadly modulated by varying the ratio of hydrophilic to hydrophobic TPU in 
the membrane. Since each TPU exhibits phase separation between the hard and soft 
segments of the copolymer, we expect that the hydrophilic and hydrophobic TPUs will be 
partially immiscible. Therefore, we hypothesize that extrusion process parameters will 
impact the homogeneity of the two components, potentially impacting the diffusion 
behavior of drugs through the membrane. 
In order to interrogate our hypotheses, we manufactured films composed of binary 
mixtures of varying composition of a hydrophilic and hydrophobic TPU using a melt 
extrusion process coupled with a roll stack to directly form thin films. The films are 
intended to represent the rate controlling membrane in a reservoir implant system. At a 
given composition, we varied extrusion process parameters to investigate the effect of 
process on key response attributes. Finally, we characterized extent of polymer mixing 
using a spectroscopic technique and drug permeability using a diffusion cell. 
2.3 MATERIALS AND METHODS 
2.3.1 Materials 
Ethylene vinyl acetate copolymer was obtained from Sigma-Aldrich (St. Louis, 
MO). EVA grades containing target vinyl acetate content of 12% (w/w), 25% (w/w), and 
40% (w/w) were purchased and are subsequently described as EVA 12, EVA 25, and 
EVA 40, respectively (Figure 2.1). We varied the vinyl acetate content of the copolymer 
in order to modulate the extent of crystallinity.  
Non-swelling thermoplastic poly(urethane) Pathway™ PY-PT60DE was obtained 
from Lubrizol (Cleveland, OH) and is described as hydrophobic TPU. Water-swelling 




Lubrizol (Cleveland, OH) and is described as hydrophilic TPU. The structures of the two 
poly(urethanes) were previously identified by 1H nuclear magnetic resonance (NMR) 
[35]. As seen in Figure 2.1, both poly(urethanes) contain hexamethylene diisocyanate as 
the hard segment and their soft segment monomer differs by two carbons. Hydrophobic 
TPU contains poly(tetrahydrofuran) as its soft segment, while hydrophilic TPU contains 






Figure 2.1: Chemical structures of (A) ethylene vinyl acetate, (B) hydrophobic TPU 
Pathway PY-PT60DE, (C) hydrophilic TPU Pathway PY-PT60DE500, and (D) 
emtricitabine. 
 
Emtricitabine (FTC), an HIV nucleoside reverse transcriptase inhibitor, was 
obtained from Laurus Labs (Hyderabad, India). As shown in Figure 2.1, it has a 
molecular weight of 247 Da, a calculated octanol/water partition coefficient (clogP) of -
1.3, and a water solubility of 112 mg/mL. As described previously, long-acting 




address the unmet need of improved patient adherence. Although emtricitabine’s potency 
is likely insufficient to be in the realm necessary to extend the duration over a significant 
length of time (e.g., ≥ 6 months), it represents a class of drugs with certain 
physicochemical properties (small, hydrophilic, water soluble) that are relevant for 
current efforts to develop implants and other sustained release formulations of HIV 
drugs. 
2.3.2 Methods 
2.3.2.1 Film Preparation 
Films were prepared using a Leistritz ZSE 18 twin-screw extruder (Somerville, 
NJ). Figure 2.2 shows the screw and barrel configurations used to manufacture the 
polymer films. The barrels were configured with a 40:1 length:diameter ratio. In the case 
of TPU film manufacture, the two polymers were charged into separate K-Tron KT20 
loss-in-weight gravimetric feeders (Sewell, NJ), which were configured to feed into a 
single port. In the case of EVA film manufacture, a single polymer was charged into a 
single K-Tron gravimetric feeder. The vent zone was connected to a vacuum, set to 1000 
mbar vacuum pressure. Table 2.1 describes the barrel configuration and temperature 
profile used to manufacture the polymer films. The barrel temperature profiles were 
selected to maximize the temperature difference between the two profiles without 
approaching the torque limit of the equipment. The extruder was connected to a Baldor 
gear pump (Mount Laurel, NJ) to dampen oscillations in flow. The end of the extruder 
featured a 0.02 x 6 inch sheet die. The extrudate was fed into a Leistritz 3-roll film stack 







Figure 2.2: Screw profiles used to manufacture polymer films on Leistritz 18 mm twin-
screw extruder. In the diagram, GFF denotes a co-rotating, non-self-wiping, conveying 
element; GFA denotes a co-rotating, intermeshing, conveying element; and KB denotes a 
kneading block. For conveying elements, the first number indicates the number of screw 
flights, the second number indicates the screw pitch in mm, and the third number 
indicates the screw length in mm. For the kneading blocks, the first number is the number 
of kneading segments, the second number is the number of screw flights, the third 
number is the length in mm, and the four number is the offset angle of the individual 
kneading segments.   Screw profile A (A) has significantly more mixing elements with a 
higher degree of offset than screw profile B (B). 
Polymer film composition (ratio of the two polymers) was varied by changing the 
ratio of the feed rates of each polymer into the extruder. Extruder processing conditions 
were varied at a given polymer composition by changing barrel temperature, screw speed, 
total feed rate, and screw design. Samples and measurements were not taken for 10 




Samples were collected and measurements recorded for 5 minutes once steady state was 
reached.  
Table 2.1: Barrel configuration and temperature profiles used to manufacture polymer 
films on Leistritz 18 mm twin-screw extruder. 






































































































































2.3.2.2 Assessment of Polymer Film Homogeneity 
Solid-state NMR (ssNMR) experiments were carried out on a 400 MHz Bruker 
(Billerica, MA) Avance III HD spectrometer (9.4 T). Polymer samples were packed into 
4 mm zirconia rotors. All spectra were acquired under a magic angle spinning (MAS) 
frequency of 12 kHz at ambient temperature and using a Bruker H/F/X probe tuned to 
1H/13C double resonance mode. 
The 1H spin-lattice relaxation time (T1) and spin-lattice relaxation time in the 
rotating frame (T1ρ) values of polymer samples were measured to evaluate the 
homogeneity of hydrophilic and hydrophobic TPU. In studies of amorphous solid 




detected relaxation measurements have been often utilized to extract relaxation values of 
drug and polymer components to evaluate their heterogeneity [44–50]. In this study 
however, we utilized a 1H-direct-detected relaxation measurement and double-component 
fitting to measure 1H T1 and T1ρ. Compared to 13C-detected experiments, a direct 
detection of 1H has much better sensitivity and thus significantly shorter acquisition time. 
The 1H spectra of the pure polymers extruded into films under similar conditions were 
measured as references. These reference spectra were utilized to quantify the hydrophilic 
and hydrophobic components. We found that the NMR quantified weight ratio of the two 
polymers matches well with the actual percentages of the two polymers in their extruded 
mixture, underscoring the quantitative nature of the 1H ssNMR method. Therefore, we 
utilized a double-component decay to fit all T1 and T1ρ curves. The ratio of the two 
components comes from the weight ratio of hydrophilic and hydrophobic polymers.  
For example, the peak areas I(τ) in 1H T1 and T1ρ measurements were integrated in 
Bruker Topspin software and fitted by the following equations: 
 , ,      (2.1) 
  
 
, ,     (2.2) 
 
Where τ is the relaxation time interval, utilizing 32 time points from 0.01 to 8 s 
for the 1H T1 and 1 to 50 ms for the 1H T1ρ measurement, respectively; S0 is the global 




components in the extruded samples, respectively. T1,1 and T1,2 for T1 and T1ρ,1 and T1ρ,2 
for T1ρ are the fitted relaxation times of the two polymer components.  
2.3.2.3 Assessment of Emtricitabine Permeability Through Polymer Films 
In order to assess changes in drug diffusion behavior through polymer films of 
different composition, apparent permeability was measured using a diffusion cell. A 
polymer film of each sample was cut using a hammer-driven hole punch and placed into 
a membrane holder. The membrane holder was spaced between two identical donor and 
acceptor chambers. Cross-type magnetic stir bars were added to each chamber. The drug 
solution was intended to model the core of a reservoir implant system, while the polymer 
film was intended to model the rate controlling membrane of the implant. A 1 mg/mL 
solution of emtricitabine in deionized water was added to the donor chamber, while pure 
deionized water was added to the acceptor chamber. The saturation solubility of 
emtricitabine in water is >100 mg/mL. A concentration of 1 mg/mL was selected to 
ensure sink conditions at early time points, such that there were sufficient time points to 
obtain an initial slope of the diffusion curve. The stirring speed was set at 400 rpm to 
minimize the boundary layer around the polymer membrane. Ultraviolet (UV) 
absorbance was measured in the acceptor chamber used a Pion Rainbow fiber optic 
system (Billerica, MA) equipped with a deuterium lamp and UV dip probes with 10 mm 
path length tips. 
In order to calculate apparent permeability, a line was fit to the linear portion of 
the concentration-time curve. The average concentration over the first 12 hours of 
concentration data, assumed to be within the lag time where no drug has diffused into the 




these two lines intersect represented the start of steady state and was the earliest time 
point used to conduct a linear regression.  The slope of the fitted line can be described as 
 and was used to determine the apparent permeability (Papp) using Fick’s first law of 
diffusion as shown in equation 2.3. 
 
         (2.3)   
       
Where V is the volume of the acceptor compartment (23 mL), A is the exposed 
surface area of the membrane (1.54 cm2), c2 is the concentration in the donor 
compartment (1 mg/mL), and c1 is the concentration is the acceptor compartment (0 
mg/mL). The concentrations for the donor and acceptor compartments used in the 
calculation are good assumptions at early time points. The diffusion study was replicated 
three times for each polymer film sample. 
2.3.2.4 Impact of Water Swelling to Polymer Film Weight and Volume 
The impact of water on polymer film geometry was investigated by assessing 
changes to both the weight and volume of the film upon exposure to water. In order to 
assess the weight gain upon swelling, we measured a dynamic vapor sorption isotherm 
using a TA Instruments Q5000 thermogravimetric analyzer (New Castle, DE). The 
polymer film sample was dried at 60°C under nitrogen purge for 3 hours or until 
<0.001% weight change over 5 minutes was observed. The sample was then equilibrated 
to 21°C and 94% RH, 96% RH, and 98% RH each for 3 days or until <0.0005% weight 
change over 5 minutes was observed. After determining the equilibrium moisture content 




extrapolated to 100% RH to obtain the water content in the polymer film when immersed 
in water. 
To assess the volume change upon swelling, we cut thin cylindrical slabs of 
polymer film and measured diameter and thickness prior to hydration using a caliper and 
thickness gauge. Each film sample was placed into a separate beaker and filled with 
approximately 20 mL of deionized water. At each time point, we removed the polymer 
film from the beaker and measured its diameter and thickness. Initial and hydrated 
volumes were determined using the measured diameter (d) and thickness (h) and equation 
4. The volume change was replicated three times for each polymer film sample.  
 
            (2.4) 
      
2.3.2.5 Statistical Analysis 
Statistical analysis was used to assess the impact of polymer mixture composition 
and extrusion process parameters on emtricitabine apparent permeability. Analysis of 
Variance (ANOVA) was conducted with bivariate fits of each parameter (composition, 
melt temperature, breakthrough time, and specific mechanical energy) on apparent 
permeability using JMP software by SAS Institute (Cary, NC). We grouped the data set 
into low and high hydrophilic polymer concentration cohorts and performed statistics 




2.4 RESULTS  
2.4.1 Film Fabrication 
We varied the independent extrusion parameters (barrel temperature profile, 
screw speed, screw profile, and feed rates) in order to affect dependent process 
parameters as shown in Table A.1. Mixture composition was calculated by dividing the 
feed rate of the hydrophilic TPU by the total feed rate. Melt temperature was measured 
directly by a flush-mounted thermocouple at the die adapter. Specific mechanical energy 
was calculated by dividing the measured screw motor power draw by the total feed rate. 
Estimated breakthrough time is a measure of residence time. Briefly, we added color-
dyed poly(ethylene) pellets to the extruder feed port while the process was running at 
steady state and recorded the time until the appearance of color was observed at the die. 
Thus, breakthrough time represents the leading edge of the residence time distribution. 
Breakthrough time was measured at several key runs. It was found to vary only with 
screw profile and total feed rate (not temperature or screw speed). Therefore, 
breakthrough time for most runs was estimated based on measurements of other runs 
using the same screw profile and total feed rate. 
By varying the extrusion process parameters, we were able to achieve a wide 
range of dependent process parameters. Over the course of the 34-run composition range, 
we were able to vary the melt temperature from 164°C to 213°C. Lower melt 
temperatures could not be obtained due to equipment torque limitations. We varied the 
breakthrough time from 46 to 127 seconds, representing a nearly three-fold range of 
residence time. Specific mechanical energy ranged from 0.17 to 0.77 kW*hr/kg, with 




2.4.2 Emtricitabine Apparent Permeability Range Through TPU Mixtures and 
EVA Grades 
We sought to investigate whether mixtures of hydrophilic and hydrophobic 
poly(urethane) would provide a broader range of apparent permeability of a hydrophilic 
drug compared with varying the vinyl acetate content of EVA. Figure 2.3 shows the 
range of emtricitabine apparent permeability achieved by either varying the 
poly(urethane) mixture composition or by varying the vinyl acetate content of the EVA 
copolymer. Varying the mixture composition between hydrophilic and hydrophobic 
poly(urethanes) offers a 736-fold range in emtricitabine apparent permeability, as 




Figure 2.3: Range of emtricitabine mean apparent permeability achieved by varying 
hydrophobic/hydrophilic TPU ratio compared with that achieved by varying EVA vinyl 





2.4.3 Effect of Poly(urethane) Mixture Composition on Emtricitabine Apparent 
Permeability with a “Well Mixed” Process 
In an effort to decouple our analysis of mixture composition and extrusion process 
impacts on permeability, we investigated the effect of poly(urethane) mixture 
composition on emtrictabine apparent permeability using only the extrusion process runs 
assumed to be “well mixed”. In other words, we selected runs extruded with high 
breakthrough time, high specific mechanical energy, and high melt temperature. As 
shown in Figure 2.4, there is a negligible change in apparent permeability over polymer 
mixture compositions between 0% and 25% (w/w) hydrophilic TPU. Between 25% and 
50% (w/w) hydrophilic TPU, there is an approximate 7-fold increase in apparent 
permeability. We observe a significant 123-fold jump in apparent permeability between 
50% and 55% (w/w) hydrophilic TPU. Finally, there is a linear increase in the drug’s 
apparent permeability through TPU membranes as the membrane composition changes 








Figure 2.4: Mean apparent permeability of emtricitabine as a function of mixture 
composition for a “well mixed” extrusion process on a log-linear scale (A) and a higher 
hydrophilic TPU concentration samples on a rectilinear scale (B). Film thickness varied 





2.4.4 Effect of the Extrusion Process on Emtricitabine Apparent Permeability 
In order to better assess the impact of extrusion process parameters on mean 
apparent permeability, the data were separated into low and high hydrophilic TPU 
concentration cohorts. Figure 2.5 offers a visual assessment of the relationship between 
the factors and the drug’s permeability. Within the low hydrophilic TPU concentration 
group, there is no significant linear relationship between composition, melt temperature, 
breakthrough time, and specific mechanical energy on emtricitabine mean apparent 
permeability. Within the high hydrophilic TPU concentration group, there is a clear linear 
relationship of apparent permeability with polymer composition. However, there is no 
apparent relationship between any of the investigated process parameters used to 
manufacture the polymer film and permeability. 
Bivariate ANOVA was performed to investigate the effect of TPU polymer 
composition and extrusion process parameters on emtricitabine apparent permeability. As 
described in Table 2.2, there was a statistically significant (p < 0.05) relationship 
observed between polymer composition and drug apparent permeability in the high 
hydrophilic TPU concentration group (>50% w/w hydrophilic TPU). However, there was 
no statistically significant effect of polymer composition on drug apparent permeability 
in the low hydrophilic TPU concentration group. Additionally, there was no statistically 
significant effect of any extrusion process parameter on emtricitabine apparent 







Figure 2.5: Effect of composition and extrusion dependent process parameters on 
emtricitabine mean apparent permeability for (A) mixtures ≤50% w/w hydrophilic TPU 
and (B) mixtures >50% w/w hydrophilic TPU.  Black points represent actual data points.  
Red line represents regression line of the bivariate fit of apparent permeability with each 
factor.  Red shaded region represents 95% confidence interval. Linear relationship 
between polymer composition and emtricitabine apparent permeability at higher 
hydrophilic TPU concentration is evident, however there is no apparent relationship 
between polymer composition and extrusion process parameters over the entire 




Table 2.2: Summary of Analysis of Variance (ANOVA) statistics assessing the 
relationship between composition and extrusion process parameters on emtricitabine 
apparent permeability. Statistically significant (p < 0.05) relationship observed between 
TPU mixture composition and emtricitabine apparent permeability in the high 
hydrophilic TPU concentration group. All other factors were not statistically significant. 
Analysis Group Factor 
Coefficient of 
Determination, r2 




Composition 0.188 2.78 0.122 
Melt Temperature 0.103 1.37 0.264 
Breakthrough Time 0.0375 0.467 0.507 




Composition 0.625 25.0 0.0002 
Melt Temperature 0.0702 1.13 0.304 
Breakthrough Time 0.0013 0.0196 0.891 
Specific Mechanical Energy 0.0724 1.17 0.296 
 
2.4.5 Effect of Polymer Composition and Extrusion Process on Polymer Film 
Homogeneity 
ssNMR relaxation measurements have been utilized to evaluate the heterogeneity 
of binary systems including polymer mixtures and drug-polymer amorphous solid 
dispersions [44–50]. Most previous studies of pharmaceutical dispersions have used 13C-
detected relaxation time measurements for making use of the resolved carbon peak of 
API and polymer. In this study, the hydrophilic and hydrophobic TPU polymers exhibit 
fully overlapped carbon peaks as shown in Figure A.1. Therefore, we established a 1H-
detected method for efficiently evaluating the miscibility of the two polymer components, 
as described in section 2.3.2.2. An example is illustrated in Figure A.2. 1H ssNMR 
spectra of extruded pure hydrophobic TPU, pure hydrophilic TPU, and a mixture 
(50.11% hydrophilic contents) are shown in the left column of A, B, and C, respectively. 




utilizing the weight percentages (i.e., 49.89% and 50.11% for hydrophobic and 
hydrophilic TPUs, respectively).  
Single component fitting was utilized for relaxation measurement of single 
component samples (i.e., pure hydrophobic and hydrophilic TPU references). Double 
component fitting for both T1 and T1 curves was utilized for the polymer mixture 
samples. In the double component fitting (equations 2.1 and 2.2), the weight fractions S1 
and S2 of the two components in the extruded samples are the corresponding weight 
percentages. A single T1 value (0.821 s) and two T1ρ values (1.79 ms and 8.86 ms) were 
identified. Interestingly, the T1 fittings gave a single value for both hydrophilic and 
hydrophobic TPU components in each TPU sample. Previous studies have determined 
that a single T1 value for a multicomponent system suggests that system is homogeneous 
at approximately 100 nm domain size [46,50].  
Table 2.3 shows the T1ρ relaxation values fitted using double-component decay by 
taking into account the weight fraction of the two polymer components. At a given 
polymer mixture composition, there is no significant change to T1ρ for each polymer or to 
the difference in T1ρ between the two polymers. Since T1ρ is expected to correlate with 
the domain size of each polymer in the mixture, we conclude that there is no effect of the 
extrusion process parameters on polymer mixture homogeneity. We observe a decrease in 
the difference in T1ρ between the two TPU polymers with increasing hydrophilic TPU 





Table 2.3: Homogeneity of poly(urethane) mixtures inferred by solid-state NMR using 
T1ρ by 1H relaxation time. All T1ρ curves are fitted well using double-component decay 
by taking weight percent of the two polymer components into account. 











100 4.04 0 - - - 
0 - 100 16.50 - - 
 
75.31 3.03 24.69 14.85 11.82 
11.26 
75.05 3.04 24.95 14.68 11.64 
75.14 2.96 24.86 13.95 10.99 
75.00 3.07 25 13.64 10.57 
 
49.89 1.79 50.11 8.86 7.07 
6.77 
49.70 1.78 50.3 8.66 6.88 
50.08 1.78 49.92 8.45 6.67 
49.12 1.73 50.88 8.20 6.47 
 
45.31 1.62 54.69 8.09 6.47 
6.31 45.94 1.62 54.06 7.98 6.36 
44.97 1.57 55.03 7.66 6.09 
 
35.88 1.37 64.12 6.77 5.40 
5.26 34.69 1.33 65.31 6.65 5.32 
35.54 1.31 64.46 6.37 5.06 
 
2.4.6 Impact of Water Swelling to Polymer Film Weight and Volume 
Figure 2.6 depicts the change in weight and volume to polymer films when they 
are immersed in water. The films exhibit a proportional increase in weight and volume 




of volume change over time reveal a relatively slow rate of water transport into the films 




Figure 2.6: (A) Equilibrium weight change at 100% RH of poly(urethane) films of 
varying mixture composition; (B) volume change in poly(urethane) films over time from 
the initial dry state. Both plots depict a proportional relationship between water uptake 
and hydrophilic TPU concentration at equilibrium. However, the volume change plot 






2.5.1 Emtricitabine Apparent Permeability Range Through TPU Mixtures and 
EVA Grades 
As demonstrated in Figure 2.3, varying the TPU grade from hydrophobic to 
hydrophilic resulted in a nearly three order of magnitude range of apparent permeability, 
compared with an approximate three-fold change in apparent permeability when varying 
the EVA grade from 12% vinyl acetate to 40% vinyl acetate. We hypothesize that the 
difference in ranges between the two polymer systems is exacerbated by the use of 
emtricitabine as the model drug. As a hydrophilic, water soluble compound, emtricitabine 
is expected to have better solubility in the water-swollen systems relative to the non-
swollen polymers. Drug dissolution in the polymer is a prerequisite for its diffusion 
through the polymer membrane.  
The same phenomenon was reported by Clark et al. in their endeavor to create a 
single intravaginal ring capable of releasing two drugs of divergent physicochemical 
properties: tenofovir, a hydrophilic molecule and levonorgestrel, a hydrophobic 
compound [38]. In order to deliver each drug molecule at its target release rate, they 
developed a segmented ring with each component composed of a different polymer. 
Consequently, a more hydrophobic drug may exhibit a wider range of apparent 
permeability between the different EVA grades. 
2.5.2 Effect of Extrusion Process on TPU Mixture Homogeneity and Emtricitabine 
Apparent Permeability 
The extrusion process parameters were ranged to the limits of the equipment, 
resulting in a 50°C range of melt temperature, a nearly 3-fold range of breakthrough time, 




observed no statistically significant changes in the polymer film properties as determined 
by ssNMR relaxation measurements and emtricitabine apparent permeability. The 
analysis suggests that the critical quality attributes of the polymer mixture are robust to 
broad changes in manufacturing process parameters.  
These findings are somewhat in contrast to prior work with aqueous coatings 
demonstrating an effect of particle size of the dispersed polymer on drug release kinetics 
[51,52]. Those studies linked the particle size of components used in mixed polymer 
membranes to a critical volume fraction necessary to form a continuous phase. Although 
our study did not explicitly vary polymer particle size, extrusion process parameters have 
been routinely correlated to extent of mixing [53–55] and may be expected to affect 
volume fraction of each component. Therefore, it was surprising to find no significant 
relationship between process parameters and homogeneity or permeability. 
The consistent homogeneity of the polymer mixture may be explained by an 
examination of the chemical structures of the two polymers (Figure 2.1). The polymers 
have identical hard segments and their soft segment monomers differ only by a length of 
two carbons [56]. Although the polymers exhibit dramatically different behavior in water, 
their similar chemistries imply good miscibility between them. Although it was not 
explicitly studied in the previously described studies identifying an effect of particle size 
on extent of mixing, we speculate that the components in those studied are immiscible. 
2.5.3 Effect of TPU Mixture Composition on Emtricitabine Apparent Permeability 
Despite the preponderance of published studies showing tablet film coats 
facilitating a range of drug release rates by varying the ratio of hydrophobic and 




change in drug apparent permeability with changes in the polymer mixture composition. 
As shown in Figure 2.4, we observed minimal effect of increasing hydrophilic TPU 
content in the mixture on emtricitabine apparent permeability at concentrations ≤50% 
(w/w) hydrophilic TPU. A statistical analysis also revealed no significant (p < 0.05) 
effect of polymer composition on emtricitabine apparent permeability at concentrations 
≤50% (w/w) hydrophilic TPU (Table 2.2). Notably, there was a proportional increase in 
polymer film weight and volume with increased hydrophilic TPU content when the 
samples were soaked in water to equilibrium time points (Figure 2.6). In other words, the 
data initially suggested that emtricitabine apparent permeability through the polymer is 
not affected by hydrophilic TPU content over this composition range, while water 
apparent permeability appears to change proportionally. 
At hydrophilic TPU concentrations 55% (w/w), the apparent permeability of 
emtricitabine through the polymer membrane increases in a linear relationship (r2 = 0.85) 
with polymer composition. An ANOVA analysis verified the statistical significance (p < 
0.05) of the relationship between drug permeability and polymer content over this 
composition range. This experimental observation is also in line with data showing a 
proportional change in polymer weight and volume with polymer mixture composition 
(Figure 2.6).  It has been previously shown that drug permeability through a polymer 
system is dependent on extent of water penetration into it [62].  As described by 
Siepmann and Peppas, water swelling results in two substantial impacts: (1) volume 
changes to the system, resulting in drug concentration changes, and (2) mobility changes 
to the polymers, leading to increased diffusivity of both water and drug.   
Most significantly, we observed an approximate 123-fold increase in 




concentration was increased from 50% to 55% (w/w). Although this mixed system of 
hydrophilic and hydrophobic TPUs has not been well studied in the literature, a patent by 
Kleiner et al. describes blending a hydrophilic TPU with a hydrophobic TPU to achieve a 
target water swelling extent and drug permeability [41]. However, the authors examined a 
single composition of 65% (w/w) hydrophilic TPU which is within the linear region of 
our data set. Consequently, although the publication might imply a broader ability to 
blend TPUs to achieve a target drug release rate, their data set was insufficient to 
comprehensively conclude such a possibility. 
In order to better understand the physical relevance of this apparent step change, 
we calculated the free diffusion coefficient of emtricitabine in water. We assumed that 
the viscosity of the solvent was slightly higher than pure water because the polymer’s 
PEO groups are likely hydrated when the polymer is immersed in water, thus increasing 
the local viscosity. In order to compare this calculation to our measured permeability 
values, we then converted the diffusion coefficient to an effective permeability by 
assuming diffusion path length through water. 
The free diffusion coefficient of emtricitabine in water can be determined using 




.         (2.5) 
The temperature (T) was assumed to be 294.15 K, the association constant (x) was 
assumed to be 2.6 for the solvent water, and the molecular weight of the solvent water 
(M) was assumed to be 18.02 Da. The viscosity of the solvent () was assumed to be 10 




glycol 3350 aqueous solution [64]. The atomic volume of emtricitabine (V) was 
calculated to be 26.9 cc/mol [65]. 
Using equation 2.5, the diffusivity of emtricitabine in water was calculated to be 
2.07 x 10-6 cm2/sec. Throughout this chapter, we have reported apparent permeability 
instead of diffusivity in order to account for film thickness variability and boundary layer 
differences between samples. In order to compare this value to our measured 
permeability values, we have calculated an effective permeability of emtricitabine 




,          (2.6) 
 
Where DFTC,water is the calculated diffusion coefficient of emtricitabine in water 
and h is the assumed thickness of the diffusion layer. The extruded polymer film 
thickness varied from 50 to 200 μm. Assuming diffusion path lengths of 50 µm and 200 
µm, we estimate the permeability of emtricitabine through water of a similar thickness to 
the TPU membranes to be in the range of 1.03 x 10-4 to 4.13 x 10-4 cm/sec. 
It is noteworthy that the estimated permeability of emtricitabine through water is 
comparable to the measured permeability of emtricitabine through the polymer 
membranes at hydrophilic TPU content 55% (w/w). This finding suggests that the 
primary path of drug diffusion through the polymer membrane over this composition 
range is through a viscous aqueous phase. 
Percolation theory may be used to explain the drug permeability behavior in the 




multicomponent, multiphase systems involving interspersions of complicated 
morphology [67]. They illustrated the concept of a percolation threshold by describing a 
hypothetical composite in which material i can exist as either isolated clusters surrounded 
by other materials or in regions that allow passage through material i from one side of the 
sample to the other without leaving material i. In this illustration, the volume fraction of 
material i,	 , can be split into the following: 
 
         (2.7) 
 
Where  is the total volume fraction of material i existing as isolated clusters, 
while  represents the total volume fraction of i that is accessible to solutes. According 
to percolation theory, if  is below a critical value, known as the percolation threshold, 
then  is zero and all of material i exists in the sample as isolated clusters. 
We propose that a percolation threshold is achieved in the system between 50 and 
55% (w/w) hydrophilic TPU [68,69]. There is insufficient hydrophilic TPU in the 
mixture to form a continuous network at concentrations ≤50% hydrophilic TPU. Figure 
2.7 depicts a two-dimensional cartoon of the proposed three-dimensional mechanism of 
drug diffusion through the TPU mixture below and above the percolation threshold. It 
depicts the hydrophobic domains as the continuous phase and the hydrophilic domains as 
the discrete phase. 
As illustrated in Figure 2.7, water diffuses into the polymer and causes 
hydrophilic domains to swell with the PEO domains of the poly(urethane) dissolved in 
the water. At concentrations below the percolation threshold, however, those hydrophilic 




hydrophobic TPU and pure hydrophilic TPU and observe diffusion through a 
hydrophobic TPU membrane to be approximately 1000-fold slower than a hydrophilic 
TPU (Figure 2.3). As drug diffuses through the polymer mixture, its transport is rate 
limited by the significantly slower rate associated with diffusivity of drug in the 
hydrophobic TPU, since a continuous hydrophilic TPU phase does not exist. 
 
 
Figure 2.7: Conceptual illustration of mechanism of drug diffusion through polymer 
mixture below and above the percolation threshold. The cartoon depicts the hydrophobic 
domains as the continuous phase and the hydrophilic domains as the discrete phase. 
Above the percolation threshold, drug is able to diffuse within the polymer entirely 
through water-filled pores. 
 
Between 50% and 55% (w/w) hydrophilic TPU content, we propose that there is 
sufficient hydrophilic polymer in the mixture to form a continuous network. Our studies 
assessing the rate and extent of water transport into the polymer mixtures (Figure 2.6) 
feature a clear differential between 50% and 55% (w/w) hydrophilic TPU compositions at 
early time points, but the difference in weight and volume increase of the 50% and 55% 




continuous phase of hydrophobic TPU is significantly slower than its transport through 
hydrophilic TPU, but the slower rate is still sufficiently fast to come to equilibrium 
within one day. We expect this is driven by the low molecular weight of water (18 Da) 
compared with the comparatively larger drug molecule (247 Da). 
The sigmoidal behavior we observe with this polymer system is more typically 
observed for mixed component systems where the discrete phase can be described as 
“porous aggregates”. As articulated by Nielsen, this system is one in which the second 
component is highly permeable to the solute but poorly dispersed [70]. This behavior was 
observed by Siepmann et al. when they compared theophylline release from pellets 
coated with aqueous dispersions of ethylcellulose and either hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) or Eudragit® L [52]. Ethylcellulose is 
insoluble in water, while both HPMCAS and Eudragit® L are anionic polymers soluble 
in aqueous media at approximately pH > 6. They observed a similar step change in the 
relationship between drug release rate and polymer mixture composition for the 
ethylcellulose/HPMCAS formulation and a relatively incremental change in drug release 
rate with polymer composition changes for the ethylcellulose/Eudragit® L system. They 
attributed the difference in behavior to the large particle size of HPMCAS, which they 
demonstrated did not disperse as well as Eudragit® L, resulting in large voids that are 
highly permeable to drug. However, our ssNMR data of the TPU system in this present 
work showing no effect of process parameters on polymer mixture homogeneity (Table 
2.3), as well as a single T1 relaxation value for all mixed TPU samples, would imply that 
the two polymers are well mixed.  
One may envision voids formed by water soluble components that dissolve when 




polymer system however, both polymers are water insoluble. Amighi et al. had 
previously studied the effect of polymer blend ratio on drug release from pellets coated 
with Eudragit® RL/Eudragit® RS mixtures [39]. The two polymers are insoluble in 
water and contain different amounts of quaternary ammonium groups, which result in 
differing mobility within the polymer networks [71]. They observed an incremental 
change in drug release rate with polymer mixture composition. Lyu et al. measured 
dexamethasone release rate from films composed of mixtures of two thermoplastic 
poly(urethanes) [61]. They observed a similar incremental change in drug release rate 
with changes in polymer mixture composition. 
We propose that our studied mixture of two water insoluble thermoplastic 
poly(urethanes) behaves more like a porous aggregate system due to two consequences of 
the water-swelling behavior of the hydrophilic TPU. Firstly, although the hydrophilic 
polymer is finely dispersed throughout the mixture in the dry state, it swells to such a 
degree that its volume fraction changes substantially in the hydrated state. As we 
described in Figure 2.6, the pure hydrophilic TPU exhibited a 365% increase in volume 
from its initial dry state after 3 days soaking in water. Secondly, the hydrophilic TPU 
domains draw in so much water that hydrophilic emtricitabine is highly permeable 
through them. 
Alternatively, one may hypothesize that increased drug permeability through the 
polymer mixture at higher hydrophilic content was simply due to increases in drug 
diffusivity driven by polymer swelling resulting in changes to free volume of diffusion 
[72]. Another potential explanation of the observed data relates to drug binding or a 
strong interaction with hydrophobic polymer domains. As hydrophilic TPU content in the 




extent of binding. However, if either of these phenomena were occurring, one would 
expect to observe a gradual increase in apparent permeability with increased hydrophilic 
TPU composition. Instead, we observe a large increase between 50% and 55% (w/w) 
hydrophilic TPU. 
2.6 CONCLUSION 
In this study, we sought to assess the feasibility of mixing hydrophobic and 
hydrophilic thermoplastic poly(urethanes) to tune the drug release rate from an implant in 
which the rate-controlling membrane was composed of the polymer mixture. We 
demonstrated the capability of varying TPU hydrophilicity to more broadly vary the 
diffusion rate of a hydrophilic model drug compared with varying the crystallinity of 
EVA. Although we showed that drug permeability through pure hydrophilic TPU was 
orders of magnitude higher than through hydrophobic TPU, we were unable to tailor drug 
release to intermediate rates. Consequently, our data suggest that the best way to tailor 
the drug release rate with thermoplastic poly(urethanes) is to select a hydrophilic TPU 
with the appropriate soft segment content to result in the desired drug diffusion rate. 
Verstraete et al. have previously demonstrated the ability to modulate the release rate of 
drugs with varying physicochemical properties by selecting thermoplastic 
poly(urethanes) of varying hydrophilicity [35].  Our proposed explanation for the 
observed behavior has not been verified with direct measurements and subsequent work 
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Chapter 3: How broadly can poly(urethane)-based implants be applied 
to drugs of varied properties?3 
3.1 ABSTRACT 
Implants offer the opportunity to improve patient adherence and real-world 
outcomes.  However, most polymers used today are hydrophobic and limit drug 
properties suitable for development.  Thermoplastic poly(urethanes) (TPUs) form pores 
upon hydration and may facilitate the development of implants containing drugs 
exhibiting broadly different properties.  We sought to investigate the effect of drug 
physicochemical properties on permeability through membranes of varying TPU mixture 
composition; leverage imaging to visualize microstructural changes to the membrane 
across the TPU mixture composition range; and quantitatively characterize the membrane 
microstructure using equivalent pore analysis.  We observed a correlation between drug 
hydrophobicity and its permeability through hydrophobic-rich TPU membranes.  
Conversely, all compounds diffused through hydrophilic-rich TPU membranes at similar 
rates, regardless of drug properties.  Imaging revealed significant microstructure 
differences between hydrophobic-rich and hydrophilic-rich TPU membranes, supporting 
hypotheses proposed in our previous study.  The hydrated hydrophilic TPU membrane 
pore area was determined to be 0.583% and its equivalent pore radius was found to be 
128 nm, suggesting that hydrophilic TPU membranes may be used to modify the release 
of small molecular weight drugs and macromolecules.  These findings highlight the 
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benefits of hydrophilic TPUs as rate-controlling membranes to modulate the release rate 
of drugs with varying physicochemical properties. 
3.2 INTRODUCTION 
Patient adherence to drug therapies remains a major obstacle to realizing the full 
therapeutic benefit of drug treatments in the real world [1].  Across a variety of 
therapeutic areas ranging from cardiovascular disease to alcoholism to infectious disease, 
studies have identified a correlation between adherence and health outcomes [2–6].  In 
response to this challenge, researchers have devoted substantial resources to develop 
products intended to improve adherence by leveraging technological capabilities or by 
changing their route of administration [7–12].   
One promising avenue to improve patient compliance and persistence is the effort 
to decrease frequency of administration.  An approach periodically used is to increase the 
drug half-life, resulting in dosing frequencies from a single dose significantly longer than 
once daily [13,14].  However, designing decreased administration frequency into the drug 
molecule itself is not always an option available to medicinal chemists.  In such cases, 
oral and parenteral modified release formulations may be useful in extending the duration 
of action [15].  Subdermal implants, in particular, have been commercially demonstrated 
to reduce the frequency of administration to as little as once every 5 years [16].  The 
ability of implants to transform a drug’s frequency of administration from once daily to 
once every 5 years has the potential to significantly enhance patient adherence by 
alleviating the patient’s need to take their medication as frequently. 
Implants may be designed as a matrix composed of drug and polymer, wherein 




polymer [17].  In such a system, the drug release rate is strongly dependent on both the 
drug load and the dosage form geometry.  Alternatively, implants can be designed as 
reservoir systems, wherein a core of drug and polymer is surrounded by a rate-controlling 
polymer membrane [18].  Since the drug release kinetics from reservoir implants are 
limited by diffusion through the rate-controlling membrane, they are capable of 
decoupling the treatment duration of a single implant from its release rate [19].   
Most commercialized implants are composed of either silicone or ethylene vinyl 
acetate (EVA).  Nexplanon® is a contraceptive reservoir implant, composed of EVA and 
designed to deliver etonogestrel, consisting of a single rod administered once every 3 
years [20].  Jadelle® is another contraceptive reservoir implant, composed of silicone and 
designed to deliver levonorgestrel, consisting of two rods administered once every 5 
years [21].  Probuphine® is a matrix implant for the treatment of opioid use disorder, 
consisting of four rods administered once every 6 months, composed of EVA and 
designed to deliver buprenorphine [17].  Researchers have also described the 
development of a subdermal implant of tenofovir alafenamide composed of silicone and a 
subdermal implant of MK-8591 composed of EVA, both designed to prevent human 
immunodeficiency virus (HIV) infection [22,23]. 
Since drug release from reservoir implants is driven by diffusion through the rate-
controlling membrane and because there is a limited ability to tune the polymer 
properties to affect drug diffusion, drug properties or duration are substantially 
constrained to effectively deliver long-acting therapeutics using implants.  For example, 
Nexplanon® provides efficacy from a single administration for up to 3 years, but 
etonogestrel is lipophilic (log P = 3.3) and highly potent (25-70 µg/day release rate) 




year duration from a single administration, but levonorgestrel is also lipophilic (log P = 
3.9) and highly potent (25-80 µg/day release rate) [26,27].  Even so, it requires two rods 
to provide the desired release rate for the 5 year duration.   
There are no commercially marketed reservoir implants composed of EVA or 
silicone intended to release a drug of substantially lower hydrophilicity than etonogestrel.  
In contrast, Supprelin® LA is a subcutaneous reservoir implant intended to deliver 
hestrelin acetate over the course of 12 months for the treatment of central precocious 
puberty [28].  The drug is hydrophilic (log P = -2.4) and the rate-controlling membrane is 
a polymethacrylate hydrogel, suggesting that it would not have diffused through rate-
controlling membranes composed of the more common EVA or silicone at sufficient 
rates [29].  Clark et al., in describing their efforts to develop a single intravaginal ring to 
deliver both hydrophobic levonorgestrel and hydrophilic tenofovir, noted that the 
hydrophobic poly(urethane) they leveraged to deliver levonorgestrel at the desired rate 
was incapable of delivering tenofovir at the desired rate [30].  To achieve their goals, 
they created a segmented ring in which levonorgestrel eluted from a hydrophobic 
poly(urethane) and tenofovir eluted from a hydrophilic poly(urethane).  These examples 
highlight the value of alternate polymer chemistry in facilitating the long-term delivery of 
medicines. 
 Thermoplastic poly(urethanes) (TPU) have been used in parenterally 
administered medical devices for decades with a good track record [31–33].  Hydrophilic 
TPUs, in which the soft segment is polyethylene oxide (PEO), have been shown to swell 
when exposed to water to an extent proportional to the PEO content in the copolymer 
[34].  Multiple studies have also demonstrated a correlation between drug release rate 




Our previous study sought to understand how mixtures of a hydrophobic and 
hydrophilic TPU could be used to modulate the diffusion behavior of the hydrophilic 
drug emtricitabine, compared with its permeability through EVA membranes of varying 
vinyl acetate content [37].  We observed a sharp increase in drug apparent permeability 
as the membrane composition changed from 50% (w/w) to 55% (w/w) hydrophilic TPU.  
We hypothesized that a continuous network of water-filled pores was formed at 
concentrations ≥55% (w/w) hydrophilic TPU (referred to as “hydrophilic-rich TPU 
compositions”), facilitating drug diffusion through the membrane.  At these hydrophilic-
rich TPU mixture compositions, we observed a nearly 700-fold increase in drug 
permeability relative to EVA.  At concentrations <50% (w/w) hydrophilic TPU (referred 
to as “hydrophobic-rich TPU compositions”), we observed the drug apparent 
permeability through the membrane to be similar to that of EVA. 
The previous study did not investigate the impact of a drug’s physicochemical 
properties on membrane permeability.  Given that EVA membranes are likely to enable 
desired release rates only for drugs with certain properties, it is important to understand 
the range of drug attributes suitable for release through TPU membranes.  The current 
study seeks to investigate the effect of drug hydrophobicity on its permeability through 
membranes of varying TPU mixture composition.  We hypothesize that drug 
hydrophobicity has a substantial impact on its diffusion rate through the TPU membrane 
at hydrophobic-rich compositions, similar to what has been observed by others for 
hydrophobic membranes [30].  In contrast, we hypothesize that drug hydrophobicity has a 
minimal impact on its permeability through the TPU membrane at hydrophilic-rich 
compositions due to the presence of water-filled pores that facilitate drug diffusion 




The previous study also did not characterize the microstructure of the TPU 
membranes, instead relying on permeability data to form conclusions [37].  However, an 
analysis of the membrane microstructure would enable a better understanding of the 
observed permeability data, including its potential application to drugs of varying 
properties.  A better understanding of the interplay between membrane microstructure 
and drug permeability may potentially aid in the rational selection or design of polymers 
for these applications.  In this study, we sought to characterize the microstructure by 
imaging changes to the membrane structure across the TPU mixture composition range.  
We also sought to understand the pore size and pore area of the TPU membrane at 
compositions above the observed percolation threshold where we believe a pore network 
exists when the membrane is hydrated. 
To assess the impact of drug lipophilicity on membrane permeability, we selected 
model drugs of similar molecular weight but different hydrophilicity.  The drugs possess 
ionizable groups, allowing us to further vary the hydrophilicity (distribution coefficient, 
log D) by changing the ionization state of each drug.  We then measured the steady-state 
diffusion rate of different drug compounds at varying pH through membranes of varying 
TPU mixture composition to establish a relationship between key drug properties and 
membrane permeability. 
Atomic force microscopy (AFM) is a surface imaging technique with the 
demonstrated ability to detect changes in both topography and material properties with 
extremely high resolution.  By using an ultramicrotome to create a flat cross section, we 
leveraged shifts in tip-sample interactions to infer changes in material properties likely 




separation between the hydrophobic- and hydrophilic-rich TPU phases, we inferred 
conclusions about the microstructure of the membrane when it is hydrated. 
Fluorescein isothiocyanate (FITC) dextrans are commercially available in 
multiple molecular weight distributions.  By measuring the steady-state diffusion rate of 
different molecular weight dextrans through the polymer membrane, we leveraged 
equivalent pore analysis to determine the porosity attributes of the membrane, including 
equivalent pore size and equivalent number of pores. 
3.3 MATERIALS AND METHODS 
3.3.1 Materials 
Emtricitabine, a human immunodeficiency virus nucleoside reverse transcriptase 
inhibitor, was obtained from Laurus Labs (Hyderabad, India).  As shown in Table 3.1, it 
has a molecular weight of 247 Da, an octanol/water partition coefficient (log P) of -0.68, 
and a pKa of 2.6.  Metoprolol tartrate, a beta blocker, was obtained from Sigma Aldrich 
(St. Louis, MO).  The free base form of the drug has a molecular weight of 267 Da, a log 
P of 1.81, and a pKa of 9.7 (Table 3.1).  Ibuprofen, a non-steroidal anti-inflammatory 
drug, was also obtained from Sigma Aldrich (St. Louis, MO).  As described in Table 3.1, 
its molecular weight is 206 Da, its log P is 3.49, and it had a pKa at 4.9.  Although the 
drugs themselves are likely to be insufficiently potent to formulate as an implant for a 
meaningful duration, they represent a range of drug physicochemical properties of 
interest to the study.  As described previously, these drug compounds were selected to 





Table 3.1: Key physicochemical properties of emtricitabine, metoprolol, and ibuprofen.  
The listed molecular weight of metoprolol tartrate reflects the free form without the 
tartrate counterion. 















267 1.81 9.7 (basic) 
Ibuprofen 
 
206 3.49 4.9 (acidic) 
 
Non-swelling thermoplastic poly(urethane) Pathway™ PY-PT60DE was obtained 
from Lubrizol (Cleveland, OH) and is described as hydrophobic TPU.  Water-swelling 
thermoplastic poly(urethane) Pathway™ PY-PT60DE500 was also obtained from 
Lubrizol (Cleveland, OH) and is described as hydrophilic TPU.  The structures of the two 
poly(urethanes) were previously identified using 1H nuclear magnetic resonance (NMR) 
[36].  As shown in Figure 3.1, both poly(urethanes) exhibit a hard segment composed of 
hexamethylene diisocyanate.  However, their soft segment monomers differ slightly with 
the hydrophobic TPU containing poly(tetrahydrofuran) as its soft segment and 








Figure 3.1: Chemical structures of (A) Pathway™ PY-PT60DE (hydrophobic TPU) and 
(B) Pathway™ PY-PT60DE500 (hydrophilic TPU). 
Fluorescein isothiocyanate (FITC) dextrans of average molecular weight 20, 40, 
250, 500, and 2000 kDa were obtained from Sigma Aldrich (St. Louis, MO).  Different 
buffers were used to control pH during the permeability studies.  We obtained 1 M pH 
3.0 acetate buffer and 0.2 M pH 7.0 phosphate buffer from Alfa Aesar (Haverhill, MA).  
We acquired 0.1 M pH 10.0 carbonate-bicarbonate buffer from Fisher (Hampton, NH).  
To obtain aqueous media at pH 12.0, we titrated 1 N sodium hydroxide obtained from 
Fisher (Hampton, NH) into deionized water. 
3.3.2 Methods 
3.3.2.1 Membrane Preparation 
This study leveraged the membranes composed of mixtures of hydrophobic and 
hydrophilic TPU described in our previous publication [37].  Briefly, films were 
manufactured using a Leistritz ZSE 18 twin-screw extruder (Somerville, NJ).  The two 
polymers were charged into separate K-Tron KT20 loss-in-weight gravimetric feeders 
(Sewell, NJ), which were configured to feed into a single extruder feed port.  The vent 
zone was connected to a vacuum pump to remove water and other volatiles from the 
system.  The extruder was connected to a Baldor gear pump (Mount Laurel, NJ) to 




The extrudate was fed into a Leistritz 3-roll film stack (Somerville, NJ).  The rolls were 
temperature controlled to 15°C.  The polymer membrane composition (ratio of the two 
polymers) was determined by changing the ratio of the feed rates of each polymer into 
the extruder. 
3.3.2.2 Drug Distribution coefficient (log D) Determination 
The distribution coefficient (log D) of each drug at each pH was determined using 
the shake-flask method.  A stock solution of each drug in methanol was added to a vial.  
Both aqueous buffer and octanol were added to the vial in equal proportions.  The vial 
was then capped and allowed to mix overnight.  The following day, the specimen was left 
to settle for at least one hour, followed by sampling of the octanol and aqueous phases.  
The samples were injected into a VMR Vydac® 218TP (Radnor, PA) C18 reverse phase 
high performance liquid chromatography column with a 4.6 mm inner diameter, 150 mm 
length, and 5 µm silica particle size.  The column was maintained at 40°C, the mobile 
phase flow rate was set at 3.0 mL/min and the detector monitored the 210 nm 
wavelength.  The mobile phase consisted of a gradient with mixtures of 0.1% (v/v) 
phosphoric acid and acetonitrile.  Over the course of the 5 minute run time, the mobile 
phase composition shifted from 5% acetonitrile to 95% acetonitrile. 
3.3.2.3 Drug Diffusivity Determination 
Two-dimensional (2D) Nuclear magnetic Resonance (NMR) Diffusion Ordered 
Spectroscopy (DOSY) was utilized to measure the diffusion coefficient of metoprolol in 
solution at different pH values.  DOSY experiments were carried out on a Bruker 
600 MHz NEO HD spectrometer equipped with a 5 mm TCI HCN helium cryoprobe with 




2D 1H DOSY spectra were collected using a standard Bruker DOSY pulse sequence 
(ledbpgp2ses) modified with the incorporation of excitation sculpting water suppression.  
The resulting diffusion coefficients were extracted from the resulting plots using the 
Bruker Dynamics Center software. 
3.3.2.4 Drug Apparent Permeability Measurement through Membranes 
This study used the same technique to measure drug apparent permeability 
through the polymer membrane as we described in our previous publication [37].  
Briefly, a polymer membrane of each sample was cut using a hammer-driven hole punch 
and placed into a membrane holder.  The membrane holder was positioned between 
identical donor and acceptor glass chambers.  Cross-type magnetic stir bars were used to 
ensure good mixing within the chamber.  The drug solution was intended to model the 
core of the reservoir implant, while the polymer film was intended to model the rate-
controlling membrane of the implant.  A drug solution in a buffer of defined pH was 
added to the donor chamber, while pure buffer was added to the acceptor chamber.  
Ultraviolet absorbance was measured in the acceptor chamber using a Pion Rainbow™ 
fiber optic system (Billerica, MA) equipped with a deuterium lamp and UV dip probes.  
Figure B.1, Figure B.2, and Figure B.3 in Appendix B: show representative concentration 
data as a function of time for emtricitabine, metoprolol, and ibuprofen, respectively. 
In order to calculate the apparent permeability, a linear regression was performed 
on the steady-state portion of the diffusion curve.  The slope of the fitted line is .  Using 





          (3.1) 
 
where V is the volume of the acceptor compartment (23 mL), A is the exposed 
surface area of the membrane (1.54 cm2), c2 is the initial drug concentration in the donor 
compartment (different for each drug) and c1 is the initial concentration in the acceptor 
compartment (0 mg/mL).  Although the drug concentration changes in the chambers 
during the diffusion study, the initial concentration used in the calculation are good 
assumptions at early time points.  Each diffusion study was replicated three times. 
3.3.2.5 Atomic Force Microscopy 
Each polymer membrane sample was placed vertically in a Leica Microsystems 0-
2 mm specimen holder (Buffalo Grove, IL).  The sample was submersed in liquid 
nitrogen for 5 minutes to harden and then quickly sectioned to be flush with the vice 
surface using a Leica Microsystems EM UC7 ultramicrotome (Buffalo Grove, IL).  Glass 
knives from 400 x 25 x 6.4 mm Leica Microsystems glass strips (Buffalo Grove, IL) were 
used for sectioning and prepared with a Leica Microsystems EM KMR3 glass knife cutter 
(Buffalo Grove, IL).  Each sample was then dried under nitrogen gas for 2 minutes to 
remove condensation associated with exposure to liquid nitrogen. 
Samples were analyzed using an Asylum Cypher ES Scanning Probe Microscope 
(Oxford Instruments, Santa Barbara, CA).  Ultra-high frequency NanoWorld Arrow™ 
UHFAuD silicon tips with gold coating on the detector side (Neuchâtel, Switzerland) 
were used for AFM sample analysis.  Samples were analyzed in air, at ambient 
conditions, using alternating contact mode and photothermal actuation (BlueDrive™) of 




optimized to maintain net repulsive tip-sample scanning (i.e., phase <90°).  Images were 
collected at 512 x 512 pixel resolution with scan rates at 6.3-6.7 Hz.  A zero-order 
flattening algorithm was applied to height images.  No correction was made for phase 
images. 
3.3.2.6  Membrane Microstructure Determination 
The apparent permeability of each dextran across the 75% (w/w) hydrophilic TPU 
membrane was determined using the method described in section 3.3.2.3 and FITC-
dextrans of varying average molecular weight.  The hydrodynamic radius of each FITC-
dextran was previously determined by Armstrong et al. by measuring the viscosity of 
FITC-dextran solutions and leveraging the Einstein viscosity relation to model the 
hydrated polymer molecules in terms of equivalent hydrodynamic spheres that would 
increase the viscosity to the same extent as solid spherical particles of equivalent volume 
[38].  The free diffusivity (D) of each FITC-dextran in water was determined from the 
hydrodynamic radius using the Stokes-Einstein equation and the known viscosity of 
water: 
 
          (3.2) 
 
Where kB is the Boltzmann constant, T is the temperature, η is the viscosity of 
water, and rh is the hydrodynamic radius. 
To characterize the pore microstructure, we leveraged a method originally 




Renkin to account for steric hindrance at the entrance to porous membranes and frictional 
resistance within the pores [39,40]. 
 
. . .     (3.3) 
 
Where Ap is the total pore area, dx is the pore length, and u is equal to  where rh 
is the hydrodynamic radius as described previously and rp is the pore radius.   
The first term establishes the condition that a molecule must pass through a pore 
opening without striking the edge.  The second term corrects for friction between the 
molecule moving within a pore and its walls.  Examining equation 3.3, we find that there 
are several known and unknown terms.  For each FITC-dextran, we have measured the 
apparent permeability through the membrane, others have determined the hydrodynamic 
radius, and we have determined free diffusivity using equation 3.2.  We assume that the 
tortuosity of the pore is negligible, and the pore length is equivalent to the measured 
membrane thickness (0.1 mm).  We utilized imaging data to assess whether our tortuosity 
assumption is reasonable, which is described in more detail in later sections.  Both Ap and 
rp are unknown and we leveraged the measured permeability data for each dextran to 
perform a non-linear fit.  In an approach utilized by several other researchers, we 
performed a chi-squared test, minimizing the difference between the calculated apparent 
permeability and the observed apparent permeability to obtain an estimate of total pore 
area and pore radius [41–43].  The total pore area relative to total membrane area, a 
measure of porosity, can then be calculated by dividing the total pore area by the total 
membrane area (1.54 cm2).  Finally, the number of equivalent pores (Np) can be 




membrane area to obtain the number of equivalent pores per unit area. 
 
          (3.4) 
   
3.4 RESULTS 
3.4.1 Effect of drug physicochemical properties on apparent permeability through 
TPU membranes 
We endeavored to investigate the impact of drug hydrophilicity on its 
permeability through TPU membranes of varying composition.  In an effort to 
quantitatively relate drug physicochemical properties to their diffusion behavior through 
poly(urethane) membranes, we measured the octanol-water distribution coefficient (log 
D) of each drug compound as a function of buffer pH.  Table 3.2 describes the octanol-
water distribution coefficient of emtricitabine, metoprolol, and ibuprofen as a function of 
buffer pH.  Based on the dissociation coefficient (pKa) of each compound, we can work 
with fully unionized drug compounds by controlling the buffer pH to pH 7 for 
emtricitabine, pH 12 for metoprolol, and pH 3 for ibuprofen.  The log D at a pH where 
the drug is in the unionized state is equivalent to the octanol-water partition coefficient 
(log P) of that compound.  Consequently, the log P for emtricitabine, metoprolol, and 
ibuprofen was measured to be -0.68, 1.81, and 3.49, respectively.  Compounds in this 
study span an approximately 10,000-fold range in partition coefficient.   
By changing the buffer pH for each compound, we can alter the ionization state 
and thus affect the hydrophilicity of the species in the permeability study.  As shown in 
Table 3.2, we observed no substantial change in the distribution coefficient of 




expect no change in ionization state between pH 7 and 10.  We measured a significant 2-
log change in the log D of metoprolol in shifting from the fully ionized state at pH 7 to 
the fully unionized state at pH 12 (Table 3.2).  We found a similar 100-fold change in the 
distribution coefficient of ibuprofen when the ionization state was shifted from fully 
unionized at pH 3 to fully ionized at pH 7 (Table 3.2).  Thus, by varying the compound 
type and buffer pH, we can obtain a range of intermediate hydrophilicities, as measured 
by log D, over a 10,000-fold range. 
Table 3.2: Shake-flask octanol-water distribution coefficient (log D) of each drug 
compound as a function of buffer pH.  Boxes containing “N/M” indicates that the 
distribution coefficient was not measured at that pH. 
Compound Calculated pKa log DpH 3 log DpH 7 log DpH 10 log DpH 12 
Emtricitabine 2.7 (basic) N/M -0.68 -0.70 N/M 
Metoprolol 9.7 (basic) N/M -0.67 1.73 1.81 
Ibuprofen 4.9 (acidic) 3.49 1.30 N/M N/M 
  
By comparing the apparent permeability of the three compounds in the unionized 
state across the TPU mixture range, we were able to assess the impact of drug 
hydrophilicity on its apparent permeability through TPU membranes both below and 
above the previously described percolation threshold [37].  Figure 3.2 describes the 
apparent permeability of unionized drug compounds as a function of TPU mixture 
composition.  We observed a strong correlation between drug hydrophilicity and its 
apparent permeability through hydrophobic-rich TPU mixtures (≤50% (w/w) hydrophilic 




rates over this TPU composition range.  Conversely, we saw a negligible effect of drug 
physicochemical properties on its apparent permeability through hydrophilic-rich TPU 
mixtures (≥55% (w/w) hydrophilic TPU). 
 
 
Figure 3.2: Mean apparent permeability (N = 3 ± SD) of unionized drug compounds 
(varying log P) as a function of TPU mixture composition.  Buffer pH was selected for 
each compound to ensure it was fully unionized during the diffusion study.  Emtricitabine 
study was conducted at pH 7, metoprolol study was conducted at pH 12, and ibuprofen 
study was conducted at pH 3. 
 
As shown in Table 3.2, metoprolol tartrate has a pKa of 9.7.  In the fully ionized 
state at pH 7, it exhibits a log D of -0.67 similar to emtricitabine.  The compound is 
partially ionized at pH 10 and its log D was determined to be 1.73, while its log D in the 
fully unionized state (pH 12) was measured at 1.81.  This nearly 100-fold change 
distribution coefficient offers an opportunity to examine the effect of hydrophilicity on 




Figure 3.3a shows the apparent permeability of metoprolol in different ionization states 
as a function of TPU mixture composition.  Similar to our finding when investigating the 
apparent permeability of different compounds of varying hydrophilicity (Figure 3.2), we 
observed a correlation between metoprolol log D and its apparent permeability through 
hydrophobic-rich TPU compositions.  We again found a negligible effect of drug 
physicochemical properties on apparent permeability through hydrophilic-rich TPU 
compositions. 
We also leveraged the pKa of ibuprofen to separately investigate the effect of 
hydrophilicity on apparent permeability while keeping most other physicochemical 
properties constant.  As described in Table 3.2, ibuprofen is fully ionized at pH 7 with a 
measured log D of 1.30 and fully unionized at pH 3 with a distribution coefficient of 
3.49.  As illustrated by Figure 3.3b, we observed a similar phenomenon to the studies 
comparing different compounds of varying log P and comparing different ionization 
states of metoprolol, with a correlation between ibuprofen distribution coefficient and its 
apparent permeability through hydrophobic-rich TPU mixtures.  For ibuprofen, there is 
an approximate 10-fold change in apparent permeability through a 25% (w/w) 
hydrophilic TPU membrane when varying ionization state.  We again found a negligible 
effect of drug physicochemical properties on ibuprofen apparent permeability through 







Figure 3.3: Mean apparent permeability (N = 3 ± SD) of metoprolol (a) and ibuprofen (b) 
at different ionization states as a function of TPU mixture composition.  Buffer pH was 
varied to affect the drug’s ionization state in each diffusion study.  For metoprolol, fully 
ionized was conducted at pH 7, partially ionized was conducted at pH 10, and fully 
unionized was conducted at pH 12.  For ibuprofen, fully ionized was conducted at pH 7 
and fully unionized was conducted at pH 3. 
The poly(urethanes) comprising the membrane do not contain ionizable groups.  




membrane in a way that would account for observed changes in drug apparent 
permeability.  However, we investigated the effect of buffer pH on the apparent 
permeability of emtricitabine over a range where there is no change to the drug’s 
ionization state as a control to ensure the observed apparent permeability changes are due 
to drug physicochemical properties.  Figure 3.4 shows the apparent permeability of 
emtricitabine through TPU membranes of varying composition at pH 7 and 10.  As is 
evident from Table 3.2, the distribution coefficient of emtricitabine does not change 
appreciably between pH 7 and 10, reflecting the fact that the compound is fully unionized 
in both environments.  Consequently, there is negligible difference in the apparent 
permeability of the drug through TPU membranes as the buffer pH is changed. 
 
 
Figure 3.4: Mean apparent permeability (N = 3 ± SD) of emtricitabine at two different 
buffer pH values (pH 7 and 10) as a function of TPU mixture composition.  Emtricitabine 
is fully unionized at both pH values.  Buffer pH was varied as a negative control to 
ensure that variations in pH had no effect on the polymer membrane in a way that would 




Although several factors may contribute to the diffusion rate of a solute (i.e., 
drug), we sought to assess whether distribution coefficient is an effective predictor of 
apparent permeability through hydrophobic-rich TPU membranes, agnostic to other 
differences between drug compounds.  Figure 3.5 describes the mean apparent 
permeability of each compound at each studied pH through both a 25% (w/w) 
hydrophilic TPU membrane (hydrophobic-rich composition) and a 75% (w/w) 
hydrophilic TPU membrane (hydrophilic-rich composition) as a function of the 
compound’s distribution coefficient (log D).  We observed a good correlation between 
mean apparent permeability of a compound through a 25% (w/w) hydrophilic TPU 
membrane and its log D, regardless of the other physicochemical features of that drug.  
The fitted relationship was exponential due to the logarithmic transformation of the 
distribution coefficient and its correlation coefficient (r2) was determined to be 0.78.  
Deviations from the fitted curve may be explained by other differences between the 
drugs.  For example, ibuprofen is 61 Da smaller than metoprolol and it is well established 
that molecular weight plays a role in the diffusion of small molecule solutes through a 
polymer [44].  In contrast, we observed no change in the mean apparent permeability 







Figure 3.5: Mean apparent permeability (N = 3 ± SD) of all studied compounds through a 
25% (w/w) hydrophilic TPU (blue diamonds) and a 75% (w/w) hydrophilic TPU (red 
squares) membrane as a function of octanol/water distribution coefficient (log D).  We 
observe a correlation between log D and mean apparent permeability at a 25% (w/w) 
hydrophilic TPU membrane composition, with a curve representing an exponential 
regression fit with a correlation coefficient (r2) value of 0.78.  However, we observe no 
correlation between log D and mean apparent permeability at a 75% (w/w) hydrophilic 
TPU membrane composition. 
We also sought to understand whether changes to a compound’s ionization state 
were affecting its diffusivity, such that these diffusivity may explain the observed 
changes in diffusion behavior.  As illustrated by equation 3.1, there is a direct 
relationship between the diffusivity of a compound and its apparent permeability through 
a membrane.  Two-dimensional DOSY NMR was utilized to determine the diffusion 
coefficient of metoprolol in solution [45].  Table 3.3 shows the measured diffusivity of 
metoprolol at each pH studied.  There is a negligible change in its diffusivity as buffer pH 
changes, suggesting that it cannot explain the observed changes in apparent permeability 





Table 3.3: Diffusivity of metoprolol in relevant pH buffers, as measured using solution 
NMR. 
Buffer pH Diffusivity (cm2/sec) 
7.0 7.22 x 10-6 
10.0 7.19 x 10-6 
12.0 7.22 x 10-6 
 
3.4.2 Nanoscale Imaging of Dry TPU Membrane Microstructure 
Atomic force microscopy enables high resolution imaging of a variety of surfaces 
and can be used to visualize the microstructure of the TPU membranes in the dry state.  
In addition to measuring changes in the height of the surface, AFM can be used to detect 
changes in material properties, such as modulus or adhesion, that may be indicative of 
phase separation.  The change in material properties is most evident in the phase image, 
which represents offsets in the resonance frequency of the tip when it meets the polymer 
surface.  However, changes in phase may also be caused by large changes in surface 
topography.  To reduce this effect, we strive to create a surface as flat as possible using 
the ultramicrotome.  Additionally, we verify that features we observe in the phase image 
that we believe to represent phase separation are not present in the height image.   
As illustrated in Figure 3.6, the topographic (height) images show a relatively flat 
surface with roughness variation below 40 nm.  Moreover, the height changes in the 
topographic images do not correspond to the contrast observed in the phase images, 
suggesting that the phase contrast is due to material property changes.  The 25% (w/w) 
hydrophilic TPU phase contrast image suggests that at this composition there is a discrete 




The hydrophilic TPU domain size appears to be in the range of 10-30 nm.  On the other 
hand, the 75% (w/w) hydrophilic TPU phase contrast image suggests that at this 
composition there is a continuous phase of hydrophilic TPU as well as discrete phases of 
hydrophobic TPU.  The hydrophilic TPU appears to be partially crystallized, forming 
microstructure consistent with lamellar crystals [46–48].  The darker regions may be 
hydrophobic TPU or amorphous phases of hydrophilic TPU.  The crystalline lamellae 
appear to be in the range of 5-15 nm thick and are very close in proximity (<5 nm) to 
each other. 
Figure 3.7 features the phase images of poly(urethane) membranes of varying 
mixture composition.  Pure hydrophobic TPU (Figure 3.7a) has a surface with no well-
defined features, whereas pure hydrophilic TPU (Figure 3.7f) exhibits features 
resembling crystalline lamellae.  We observed a significant change in the membrane 
microstructure between 25% (w/w) hydrophilic TPU (Figure 3.7b) and 55% (w/w) 
hydrophilic TPU (Figure 3.7d), with 50% (w/w) hydrophilic TPU (Figure 3.7c) 
exhibiting an intermediate microstructure to the former two compositions.  We were 
unable to discern a substantial structural difference between 55% (w/w) hydrophilic TPU 
(Figure 3.7d), 75% (w/w) hydrophilic TPU (Figure 3.7e), and 100% hydrophilic TPU 
(Figure 3.7f), although it is possible that the lamellar structures are more densely packed 





(a)    
(b)    
Figure 3.6: AFM height (left) and phase (right) images of (a) a dry 25% (w/w) 






(a)     (b)   
(c)     (d)   
(e)    (f)  
Figure 3.7: Phase images of dry TPU membranes of varying composition.  Membrane 
composition is as follows: 0% (w/w) hydrophilic TPU (a); 25% (w/w) hydrophilic TPU 
(b); 50% (w/w) hydrophilic TPU (c); 55% (w/w) hydrophilic TPU (d); 75% (w/w) 
hydrophilic TPU (e); and 100% (w/w) hydrophilic TPU (f). 
3.4.3 Hydrated Membrane Microstructure Characterization 
By comparing our measured apparent permeability values of FITC-dextrans with 
varying average molecular weight and leveraging the previously determined 
hydrodynamic radius of FITC-dextrans, we were able to relate the hydrodynamic radius 




comparison of our measured mean apparent permeability of each FITC-dextran of 
varying average molecular weight through a 75% (w/w) hydrophilic TPU membrane 
(hydrophilic-rich composition) and the previously determined hydrodynamic radius of 
that dextran.  As expected, there is a clear downward trend in mean apparent permeability 
with increasing hydrodynamic radius. 
Table 3.4: Comparison of the measured mean apparent permeability through a 75% 
(w/w) hydrophilic TPU membrane of FITC-dextrans of varying nominal molecular 
weight.  Hydrodynamic radius of the FITC-dextrans was previously determined by 









20 3.24 4.71 x 10-7 
40 4.78 3.26 x 10-7 
250 11.46 1.12 x 10-7 
500 15.9 7.03 x 10-8 
2000 26.89 2.54 x 10-8 
 
As we described in section 3.3.2.6, we performed a non-linear fit of equation 3.3 
using the hydrodynamic radius and mean apparent permeability data listed in Table 3.4, 
solving for the equivalent pore radius (rp) and the total pore area available for diffusion 
relative to the pore length (Ap/dx).  As outlined in Table 3.2, our analysis found Ap/dx to 
be 0.898 cm.  Assuming minimal pore tortuosity such that the pore length is similar to the 




Since the total membrane area was measured at 1.54 cm2, we observed that the pore area 
was 0.583% relative to the total membrane area.  The equivalent pore radius (rp) was 
found to be 128 nm.  By using equation 3.4, we determined the equivalent number of 
pores (Np) to be 1.14 x 107 pores/cm2. 
3.5 DISCUSSION 
3.5.1 Effect of drug physicochemical properties on apparent permeability through 
TPU membranes 
As in our previous study, we observed a clear bifurcation in the behavior of the 
mixed TPU membrane system across drugs of varying physicochemical properties [37].  
As we proposed in that publication, for membranes composed of low hydrophilic TPU 
concentration, drug must diffuse through hydrophobic TPU polymer domains to move 
from the donor to the acceptor chamber.  For the drug to diffuse through the polymer, it 
must dissolve into it [49].  Multiple previous studies have identified a drug’s 
hydrophobicity, typically quantified by its octanol/water partition coefficient, as a 
significant contributor to its solubility [50,51].  Therefore, it is not surprising that the 
physicochemical properties of a drug compound would influence its ability to diffuse 
through the membrane. 
We have shown that the drug’s hydrophilicity, as quantified by its octanol/water 
distribution coefficient, correlates with its diffusion rate through the membrane at low 
hydrophilic TPU compositions (Figure 3.2 and Figure 3.3).  This phenomenon is 
observed with compounds of different structural features that have inherently different 
polarity, as well as for a given drug as it transitions between different ionization states.  It 
is remarkable how strongly the distribution coefficient is a determinant of membrane 




(Figure 3.5).  Specifically, we observed that hydrophobic unionized ibuprofen (log D = 
3.49, Table 3.2) exhibited similar apparent permeability through hydrophobic-rich TPU 
membranes as through water-filled pores of hydrophilic-rich TPU membranes (Figure 
3.3b).  We would envision that hydrophobic TPU is a broadly similar hydrophobic 
environment for the drug to EVA or silicone, although specific diffusion rates may vary.  
Compounds of a similar hydrophobic character would be expected to diffuse through the 
hydrophobic membrane at a reasonably fast rate to elute effective drug levels.  Perhaps 
not coincidentally, both etonogestrel and levonorgestrel are available commercially as 
reservoir implants in which drug must diffuse through a hydrophobic EVA or silicone 
membrane and both compounds have octanol/water partition coefficients similar to or 
greater than ibuprofen [20,21].    
Another possible explanation for the observed change in apparent permeability 
between different drug compounds and within a given drug compound at different 
ionization states is that the diffusivity of the compound may be changing.  We 
deliberately selected drug molecules of similar molecular weight to minimize the effect 
of diffusivity differences on their membrane permeability.  However, others have 
demonstrated a relationship between the ionization status of a solute and its diffusion 
coefficient [52].  Therefore, we measured the diffusivity of metoprolol for each pH at 
which we chose to conduct the permeability studies.  Table 3.3 highlights the negligible 
change in diffusivity of the compound as a function of ionization state.  Consequently, we 
conclude that shifts in the hydrophobicity of the drug species are the primary cause of the 
observed changes in membrane permeability. 
We have also demonstrated that the change in apparent permeability of the drug 




to the membrane itself.  Figure 3.4 illustrates the measured apparent permeability of 
emtricitabine at pH 7 and pH 10.  As shown in Table 3.2, there is no substantial 
difference in the log D of emtricitabine between pH 7 and 10, which is expected based on 
its pKa at 2.7.  There was no observed difference in emtricitabine apparent permeability 
across the TPU composition range between pH 7 and 10, underscoring the relevance of 
drug physicochemical properties as the driver of permeability changes in our study.  
However, our conclusion that environmental pH does not cause changes to the membrane 
itself is driven by an assessment using a single drug. 
For membranes composed of high hydrophilic TPU concentrations, above the 
percolation threshold that we proposed in which a continuous network of water-filled 
pores is formed, drug may diffuse through the pores to move from the donor to the 
acceptor chamber [37].  In this way, drug is largely able to avoid polymer interactions as 
a major determinant of its diffusion rate.  Consequently, we observed minimal differences 
in apparent permeability through the TPU membranes at hydrophilic TPU compositions 
≥55% (w/w) hydrophilic TPU, regardless of the drug compound or ionization state 
studied.   
This finding has substantial implications for the development of implants and 
other pharmaceutical dosage forms where hydrophilic TPUs may be used as a rate-
controlling membrane.  We have demonstrated that diffusion rate through the membrane 
is not sensitive to drug physicochemical properties, suggesting that drug release rate may 
be controlled by modifying the microstructure of the TPU pore network, largely 
irrespective of the properties of the drug of interest.  Our study suggests that modulating 
membrane microstructure by mixing TPUs of varying hydrophilicity has limitations.  




composition range and it changes dramatically over the composition range representing 
the percolation threshold.  Changing the TPU pore network microstructure can be 
achieved by varying the hard segment to soft segment ratio of the TPU.  While the 
consequences of this behavior are exciting, it’s important to acknowledge that we do 
expect some physicochemical properties of the drug to impact its diffusion through 
hydrophilic TPU membranes.  For example, it is well established that molecular weight 
impacts a solute’s diffusion rate through a polymer [53].  We observed this phenomenon 
in our study in comparing the apparent permeability of FITC-dextrans of varying average 
molecular weight through a TPU membrane (Table 3.4).  
3.5.2 Nanoscale Imaging of Dry TPU Membrane Microstructure 
We sought to leverage atomic force microscopy to visualize the microstructure of 
the TPU membranes and assess whether our proposed hypothesis could be supported by 
the imaging data.  The observed microstructure of the dry membranes as a function of 
TPU mixture composition (Figure 3.7) is generally similar to the hypothesized structure 
represented by the cartoon depicted by Lowinger et al. (Figure 3.8a) [37].  The AFM 
images support the depiction of hydrophobic TPU domains as the continuous phase and 
hydrophilic TPU domains as the discrete phase below the percolation threshold.  At low 
hydrophilic TPU compositions, we observed a discrete phase well-dispersed in a separate 
continuous phase.  We propose that the discrete phase is amorphous hydrophilic TPU and 
the continuous phase is hydrophobic TPU.  The hydrophilic TPU domain size is in the 
range of 10-30 nm, although we would expect the domain size to increase when the 
polymer is hydrated.  We have previously shown that the hydrophilic TPU swells 







Figure 3.8: Conceptual illustration of mechanism of drug diffusion through polymer 
mixture below and above the percolation threshold.  The cartoon depicts the hydrophobic 
domains as the continuous phase and the hydrophilic domains as the discrete phase.  
Above the percolation threshold, drug can diffuse within the polymer entirely through 
water-filled pores.  (a) The cartoon as depicted in Lowinger et al. based on emtricitabine 
apparent permeability data.  Adapted from [37], Elsevier, 2019 with permission.  (b) The 
cartoon as revised based on the additional characterization data gathered in this study. 
If a drug were to diffuse from one side of the membrane to the other, it would 
necessarily pass through regions of hydrophobic TPU.  Therefore, its diffusion through 




membrane.  This microstructural feature also explains why there is a negligible difference 
in apparent permeability between pure hydrophobic TPU membranes and those 
composed of 25% (w/w) hydrophilic TPU across all drugs and ionization states 
investigated.  The addition of 25% (w/w) hydrophilic TPU to the membrane does not 
change the inevitability that the drug must diffuse through regions of hydrophilic TPU. 
We also observed evidence that a continuous network of hydrophilic TPU is 
present at compositions above the percolation threshold, as previously proposed in Figure 
3.8a.  We did not predict that the hydrophilic TPU domains would crystallize into a 
lamellar structure.  In retrospect, however, the observation of crystalline domains is not 
surprising.  Poly(ethylene oxide) (PEO), a constituent of the hydrophilic TPU copolymer, 
is known to crystallize into a semi-crystalline polymer at room temperature [54].  It has 
also been well established that crystallization of polymer chains follows a morphology 
where the chains fold back and forth to form lamellae with a thickness of 10-20 nm that 
will grow isotropically to form spherulites [55].  Wang et al. performed an interesting 
study to investigate the crystallization of PEO in a confined environment wherein the 
polymer was coextruded in alternating nanolayers with ethylene-co-acrylic acid [56].  
Among other findings, they observed that when the thickness of the nanolayer was 
confined by another polymer phase, the PEO crystallized as single, high aspect ratio 
lamellae.  Therefore, it may be expected that a mixed polymer system in which the 
hydrophilic PEO-containing TPU copolymer forms a continuous network but which is 
still constrained by a hydrophobic TPU polymer phase would form crystalline lamellae of 
5-15 nm thickness as observed. 
It is important to note that the images depicted in Figure 3.7 are of dry polymer 




the membrane is an aqueous one where the polymer is hydrated.  PEO is a water soluble 
polymer [57] and we would expect the crystalline PEO portions of the hydrophilic TPU 
that we observe in the images to dissolve when the polymer is hydrated, forming the 
water-filled pores.  In other words, we would expect that water-filled pores would be 
present in the hydrated membrane where we observe crystalline lamellar regions in the 
dry AFM images.  However, the hydrophilic TPU polymers swell when hydrated [36,37].  
Consequently, we would expect the thickness of the lamellar phase to expand when the 
polymer hydrates.  Since the images reveal that the 5-15 nm thick lamellae are very close 
(<5 nm) in proximity to each other, it is conceivable that multiple PEO lamellae coalesce 
when hydrated into a larger water-filled pore.  This proposal helps to reconcile the dry 
AFM images with equivalent pore radius of 128 nm determined using FITC-dextran 
permeability measurements and equivalent pore analysis (Table 3.5). 
The 50% (w/w) hydrophilic TPU image (Figure 3.7c) represents intermediate 
structural features to the features exhibited at those compositions directly below and 
above it.  It is evident that hydrophilic TPU has begun to crystallize and exhibit a longer-
range network.  However, we can observe disruptions to the lamellar network at the 50% 
(w/w) hydrophilic TPU composition that we do not see at higher concentration TPU 
images.  Based on these data, we would expect a drug to diffuse faster through the 50% 
(w/w) hydrophilic TPU membrane, but substantially slower than through the 55% (w/w) 
hydrophilic TPU membrane because it still must periodically diffuse through small 
hydrophobic TPU domains.  Indeed, we observe this diffusion behavior with both 
emtricitabine (Figure 3.4) and metoprolol under a variety of ionization states (Figure 
3.3a).  The significant change in diffusion rate between 25%, 50%, and 55% (w/w) 




unionized ibuprofen is significantly more hydrophobic than the other drug species and 
can diffuse through hydrophobic TPU domains at rates similar to its diffusion through 
water-filled pores. 
3.5.3 Hydrated Membrane Microstructure Characterization 
Although AFM imaging provides valuable insight into the microstructure of the 
TPU membranes, we sought an orthogonal approach to address two gaps.  Firstly, while 
imaging can be a powerful tool to visualize structural changes to the membrane as TPU 
mixture composition changes, it is qualitative and is therefore inherently more subjective 
than a more quantitative technique.  Secondly, the AFM membranes were imaged in the 
dry state and we made inferences about how they would behave in the hydrated state.  By 
using an equivalent pore analysis approach, we were able to quantitatively characterize 
the TPU membranes in the hydrated state. 
When determining the total pore area available for diffusion, we assumed that the 
pore length in the hydrated membrane was equivalent to the membrane thickness.  That 
is, we assumed there is no tortuosity to the pores.  Although there is certainly some 
tortuosity to the pore in reality, the extensive network suggested by the AFM images 
(Figure 3.7) suggests that tortuosity is low.  Consequently, we believe that a reasonable 
approximation of the pore length is the membrane thickness. 
The total pore area relative to the total membrane area (0.583%) described in 
Table 3.5 provides a quantitative measure of membrane porosity.  Membrane porosity 
would typically be expressed as a fraction of the total membrane volume, rather than 
area, taken up by pores.  However, the AFM images suggest that water-filled pores are 




apparent preferred orientation to the pores, we can assume that the area fraction 
consumed by pores is equivalent to the volume fraction taken up by pores.  By selecting a 
hydrophilic TPU composed of a lower soft segment content, with a lower extent of 
swelling, we would expect the total pore area relative to the total membrane area to 
decrease, constituting a mechanism to modulate drug release rate. 
Table 3.5: Outcome of 75% (w/w) hydrophilic TPU membrane microstructure analysis 
using FITC-dextrans of varying nominal molecular weight. 
Total pore area available for diffusion/pore length (Ap/dx) 0.898 cm 
Total pore area (Ap) assuming 100 µm pore length 0.00898 cm2 
Pore area relative to total membrane area 0.583% 
Equivalent number of pores (Np) 1.14 x 107 pores/cm2 
Equivalent pore radius (rp) 128 nm 
 
The equivalent pore radius approximates the maximum size of a molecule that can 
diffuse through a homogeneous pore population but assumes that the molecule is 
spherical.  Dextrans are known to exhibit a rod shape, more closely resembling an 
ellipsoid [58].  The free diffusion of rod-shaped solutes in a liquid medium has been 
found to correlate with its longer dimension.  In contrast, the diffusion of rod-shaped 
solutes through polymers has been shown to correlate with its shorter dimension [59].  
The diffusion of rod-shaped dextrans is expected to occur by entering the pore with the 




determination and the estimates of equivalent pore attributes described in this study 
represent only an upper end approximation of the microstructure. 
However, the determined equivalent pore radius (128 nm) shown in Table 3.5 is 
substantially larger than the hydrodynamic radii of small and macromolecules.  
Armstrong et al. reported that a variety of therapeutic antibodies exhibited hydrodynamic 
radii in the range of 3-7 nm, with the largest macromolecules they studied having a 
hydrodynamic radius of approximately 25 nm.  Therefore, despite any inaccuracies in the 
membrane microstructure caused by our assumptions, we would expect rate-controlling 
membranes composed of hydrophilic TPUs can release both small and large drug 
molecules. 
3.6 CONCLUSION 
As part of this investigation, we sought to more deeply understand the findings 
from our previous study.  We examined the effect of drug physicochemical properties on 
their diffusion through rate-controlling membranes composed of TPU mixtures.  We 
identified a substantial correlation between a drug’s distribution coefficient and its 
apparent permeability through membranes at TPU mixture compositions below the 
percolation threshold.  We believe this behavior broadly represents the relationship 
between drug properties and their release through EVA and silicone, the dominant 
materials used in commercial implants.  In contrast, we observed a minimal effect of drug 
hydrophobicity on its apparent permeability through membranes at hydrophilic-rich TPU 
mixture compositions.  Our finding suggests that implants with rate-controlling 




rate based on the swelling behavior of the selected TPU, largely irrespective of drug 
hydrophobicity. 
We leveraged a nanoscale imaging approach to visualize changes to the dry 
membrane microstructure across the TPU mixture composition range.  We found that the 
membrane images broadly reflected the conceptual microstructure that we proposed in 
our previous study.  We observed a discrete phase of hydrophilic TPU dispersed in a 
continuous phase of hydrophobic TPU at TPU mixture compositions below the 
percolation threshold.  We found that the PEO segments of the hydrophilic TPU 
crystallized into lamellar structures at TPU mixture compositions above the percolation 
threshold, which are expected to dissolve, swell, and coalesce into water-filled pores 
when the membrane is hydrated.  Consequently, we can bolster our confidence in the 
conclusion that drug release through implants with rate-controlling membranes composed 
of hydrophilic TPU will not be sensitive to drug hydrophobicity. 
Finally, we performed an equivalent pore analysis to determine the membrane 
pore area of 0.583% of the 75% (w/w) hydrophilic TPU membrane.  We estimated the 
equivalent pore radius at 128 nm, importantly finding that rate-controlling membranes 
composed of hydrophilic TPU can release both small and macromolecule drugs through 
their water-filled pore mechanism.  Future work should investigate the tunability of both 
small and large molecule drug diffusion rate by varying the soft segment content of 
hydrophilic poly(urethane) membranes. 
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Chapter 4: Hydrophilic poly(urethanes) are an effective tool for gastric 
retention independent of drug release rate4 
4.1 ABSTRACT 
Acyclovir is a poorly permeable, short half-life drug with poor colonic absorption, 
and current conventional controlled release formulations are unable to decrease the 
frequency of administration.  We designed acyclovir dosage forms to be administered 
less frequently by being retained in the stomach and releasing drug over an extended 
duration.  We developed a conventional modified-release matrix tablet to sustain the 
release of acyclovir and surrounded it with a hydrophilic poly(urethane) layer.  When 
hydrated, the porous poly(urethane) swells to a size near or beyond that of the relaxed 
pylorus diameter and does not affect drug release rate.  We demonstrated that the 
formulation is retained in the stomach for extended durations as it slowly releases drug, 
allowing for similar AUC but delayed tmax relative to a non-gastroretentive control tablet.  
Unlike many other gastroretentive formulations, this dosage form design decouples drug 
release rate from gastric retention time, allowing them to be modulated independently.  It 
also effectively retains in the stomach regardless of prandial state, differentiating from 
other approaches.  Our direct observation of excised rat stomachs allowed for a rigorous 
assessment of the impact of polymer swelling extent and prandial state on both the 
dosage form integrity and retention time. 
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Pharmaceutical researchers have attempted gastric retention for decades as a 
technique to improve the pharmacokinetic (PK) properties of drugs with oral absorption 
challenges.  Increasing the gastric residence time may be useful for drugs that are locally 
active in the stomach [1–4], have a narrow absorption window [5–8], are unstable in the 
intestinal environment [9], or which exhibit poor solubility at intestinal pH [10–12].  By 
virtue of increasing the overall gastrointestinal residence time, gastric retention may be 
used to develop an extended release drug product with reduced frequency of 
administration and improved patient adherence [13]. 
A key challenge in successfully achieving gastric retention relates to the 
physiological environment.  The process of gastric emptying is determined by the 
interdigestive migrating myoelectric complex (MMC), which cycles through the stomach 
and small intestine every 1.5-2 hours [14].  Gastroretentive (GR) dosage forms aim to 
overcome the MMC process in which the stomach removes large, undigested material 
during Phase III [15].  The main approaches undertaken by researchers to retain a dosage 
form in the stomach can be generally grouped into floating, mucoadhesive, and 
expandable systems. 
The design intent of floating systems is to achieve gastric retention by keeping the 
dosage form away from the pylorus.  Such systems are characterized by their capacity to 
float in and over the gastric content due to their low density [16].  This approach, 
however, requires the presence of stomach contents on which the dosage form can float.  
Since water empties rapidly from the stomach, there is an implicit requirement for food to 
be present in order to obtain a long gastric retention time [15].  Indeed, several clinical 




retention time and food intake, making it difficult to envision consistent success in the 
fasted state [1,17]. 
Since their introduction several decades ago, mucoadhesive systems have 
attracted research interest to extend gastric retention time [18].  Designed to adhere to the 
stomach mucosal membrane, these systems must be able to resist high gastric motility 
and continual renewal of the mucus lining [19].  Consequently, multiple studies 
investigating the utility of mucoadhesive systems were able to identify evidence of 
gastric retention under fasted conditions [20–22].  Some limited preclinical successes 
with mucoadhesive systems have been reported.  Patil and Talele developed a 
mucoadhesive gastroretentive tablet of lafutidine containing xanthan gum [23].  They 
performed x-ray imaging on rabbits and determined that their tablet retained in the 
stomach for over 10 hours.  Pandey et al. prepared a mucoadhesive patch of lercanidipine 
HCl, using a combination of Eudragit RS and RL [24].  They assessed mucoadhesion by 
performing an ex vivo study using rat stomach mucosa and confirmed in a rabbit PK 
study that their formulation substantially increased gastrointestinal residence time.  
However, in both studies, the dosage forms also swelled substantially, so the specific 
mechanism of gastric retention is not clear.  
Expandable systems are designed to increase in size to dimensions greater than 
those of the pyloric sphincter, thereby physically preventing the dosage form emptying 
from the stomach.  To allow for facile administration, the dosage forms must be easily 
swallowed and increase in size significantly once inside the stomach [25].  Unfolding 
systems are composed of elastomers that unfold in the stomach [26–28].  Swelling 
systems utilize polymers with extensive swelling characteristics upon hydration [29–32].  




systems must expand to a size greater than the pyloric diameter to achieve gastric 
retention.  Keet used radiological imaging to measure the relaxed pyloric diameter in 10 
normal subjects and found its size to be 11-19 mm across the individuals studied [33].  
Munk et al. measured the resting pylorus in the presence of food and determined it to be 
12.8 ± 7.0 mm [34].  Lalloo et al. proposed that a formulation should swell to >15-16 mm 
in order to retain in the stomach [15]. 
Although many approaches undertaken to develop gastroretentive formulations 
have not translated into clinically successful drug products, some have demonstrated 
success including Glumetza®, Proquin® XR, and Gralise® [13].  We chose to focus on 
Gralise® as a comparator, which is a once daily tablet of gabapentin intended to retain in 
the stomach for extended durations.  Gralise® tablets contain poly(ethylene oxide) (PEO) 
and hydroxypropyl methylcellulose, which swell when hydrated and form a matrix to 
control the drug release rate.  Chen et al. reported that when compared with an immediate 
release gabapentin product, Gralise® exhibited a longer time (tmax) to reach a lower peak 
plasma concentration (Cmax) [35].  To the extent that its formulation plays a role in 
stomach retention, the same polymers are used to swell the tablet and modulate drug 
release, such that these two attributes cannot be decoupled. 
Thermoplastic poly(urethanes) (TPUs) have been applied to implanted medical 
devices for decades [36–38].  There has also been a substantial amount of research 
performed on the use of poly(urethanes) to deliver drugs orally [39–43].  Claeys et al. 
studied the impact of dicarboxylic acids on the release behavior of melt extruded and 
injection molded hydrophobic poly(urethane) tablets containing diprophylline [44].  
Verstraete et al. followed up on that work by investigating the ability of hydrophilic 




need for a third component [45].  These hydrophilic TPUs, where the soft segment is 
PEO, are water insoluble yet have been shown to swell in water proportional to the PEO 
content in the copolymer [46].  We have recently studied the underlying mechanism of 
drug transport through hydrophilic poly(urethanes) and demonstrated that a pore network 
is formed when the polymer is hydrated [47].  We also found that the diffusion of small 
molecule drugs through the hydrophilic TPU pore network is relatively fast and 
insensitive to drug physicochemical properties.  The properties of hydrophilic TPU may 
be suitable for gastric retention, whereby the substantial swelling of the polymer 
physically prevents passing through the pylorus while the pore network allows for drug 
release at a rate dictated by other attributes of the dosage form. 
Acyclovir is a guanosine-analogue antiviral drug used to treat herpes-simplex and 
varicella-zoster virus infections [48].  It is available to be administered as an oral tablet, a 
topical cream, an ophthalmic ointment, and as an intravenous injection [49].  Despite its 
relatively high water solubility (1.82 mg/mL), acyclovir exhibits poor oral bioavailability 
of only 15-20% [48,50].  The drug’s poor absorption behavior is likely driven by its low 
intestinal permeability, leading to high administered doses [51].  Moreover, acyclovir 
exhibits a short elimination half-life of 2-3 hours, resulting in the need for patients to take 
tablets as often as five times per day [48].  The high frequency of administration may 
present adherence challenges as long term administration of acyclovir (6 months or 
longer) is required in patients with relapsing herpes-simplex infection [52].   The drug is 
predominantly absorbed from the upper gastrointestinal tract, making it unlikely for 
conventional sustained release formulations to effectively reduce frequency of 
administration [53].  However, acyclovir’s poor colonic absorption and short half-life 




potential to reduce the frequency of administration.  Indeed, others have tried various 
gastroretentive approaches to improve the pharmacokinetics of this drug [54–57].  
We sought to develop a dosage form of acyclovir that could be administered less 
frequently by being retained in the stomach and releasing drug over a 6-12 hour time 
period.  Our approach was to develop a conventional controlled release matrix tablet to 
sustain the release of acyclovir over the 6-12 hour time period and surround the matrix 
tablet with an outer layer composed of hydrophilic TPU.  When the tablet is hydrated, the 
hydrophilic TPU layer swells beyond the size of the relaxed pylorus, providing a robust 
mechanism for gastric retention.  We hypothesized that formulating acyclovir in such a 
dosage form will retain the tablet in the stomach as it slowly releases drug, allowing for 
similar area under the curve (AUC) but delayed tmax relative to an immediate release 
control.  Unlike many other gastroretentive formulations, this dosage form design 
decouples drug release rate from gastric retention time, allowing them to be modulated 
independently.  We tested our hypothesis by conducting rat studies in which the stomach 
retention behavior of the dosage form was directly observed, in addition to comparing the 
pharmacokinetics of a control formulation to our gastroretentive dosage form. 
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Acyclovir was purchased from Carbosynth Limited (Berkshire, UK).  Hydrophilic 
poly(urethanes) Pathway™ PY-PT60DE500 and PY-PT60DE2000 and hydrophobic 
poly(urethane) Pathway™ PY-PT60DE were obtained from Lubrizol (Cleveland, OH).  
Microcrystalline cellulose Avicel® PH-102, hydroxypropyl methylcellulose (HPMC) 




MI).  Lactose 316 was purchased from Kerry (Tralee, Ireland).  Magnesium stearate was 
purchased from Mallinckrodt (Staines-upon-Thames, UK).  Size 9 hard gelatin capsules 
were obtained from Torpac (Fairfield, NJ).  Gabapentin drug substance was purchased 
from Sigma-Aldrich (St. Louis, MO).  Gralise® 300 mg potency tablets were acquired 
from Assertio Therapeutics (Newark, CA).  0.1N hydrochloric acid (HCl) solution was 
purchased from Fisher (Hampton, NH).  Acetonitrile and water were of HPLC grade.  All 
other chemicals and reagents were of ACS grade or better. 
4.3.2 Methods 
4.3.2.1 Dosage Form Preparation and Characterization 
Physical blends were weighed according to the compositions described in  
 
Table 4.1 and Table 4.2 for acyclovir immediate release (IR) and controlled 
release (CR) formulations, respectively.  The only compositional difference between the 
immediate and controlled release formulations was the addition of 20% (w/w) 
hydroxypropyl methylcellulose (HPMC) K4M to the controlled release formulation.  The 
composition of the minitablet CR formulation used for rat studies is shown in Table 4.3.  
The only compositional difference between the large tablet and the minitablet controlled 
release formulation compositions is the grade of HPMC, changed from K4M to K100M.  
This change reflects the increased surface area of minitablets, necessitating a higher 
viscosity polymer to obtain similar drug release rate. 
All components except magnesium stearate were added to glass bottles and mixed 
for 10 minutes using a Glen Mills Turbula mixer (Clifton, NJ).  Magnesium stearate was 




2 minutes.  Blends were compressed with a Roland Research Devices compaction 
simulator (Ewing, NJ) using 17.02 x 6.73 mm tooling from Elizabeth Carbide 
(McKeesport, PA) for the large immediate release and controlled release tablets to 
prepare 200 mg potency tablets.  The controlled release minitablets were compressed 
using 1.5 mm diameter 18-tip tooling from Elizabeth Carbide to prepare 1 mg potency 
minitablets.  The large immediate release tablets were compressed with a 15 kN force to a 
hardness of 29 kP.  The large controlled release tablets were compressed with a 12 kN 
force to a hardness of 20 kP, while the controlled release minitablets were compressed 
with a 12 kN force. 
 
Table 4.1: Core tablet composition for immediate release acyclovir formulation. 
Component Composition (% w/w) Weight/Tablet (mg) 




Lactose 316 33% 220 
Croscarmellose sodium 3% 20.0 
Magnesium stearate 1% 6.70 
 
Table 4.2: Core tablet composition for controlled release acyclovir matrix formulation. 
Component Composition (% w/w) Weight/Tablet (mg) 








Croscarmellose sodium 3% 20.0 





Table 4.3: Core tablet composition for minitablet controlled release acyclovir matrix 
formulation. 
Component Composition (% w/w) Weight/Tablet (mg) 








Croscarmellose sodium 3% 20.0 
Magnesium stearate 1% 6.70 
 
Poly(urethane) films with two different swelling extents were prepared in 
different ways.  The greater swelling (100% TPU2000) film was prepared by drying PY-
PT60DE2000 polymer pellets overnight in a vacuum oven set to 40°C with 200 mbar 
absolute pressure, followed by compression at 700 lbf on an Automated Carver Press 
(Wabash, IN) between two poly(tetrafluoroethylene)-coated sheets at 180°C for a 5 
minute dwell time.  The film was then cooled for at least 15 minutes in a 5°C refrigerator.  
The lesser swelling (75% TPU500) film was prepared according to a procedure described 
elsewhere [58].  Briefly, it was manufactured using a Leistritz ZSE 18 twin-screw 
extruder (Somerville, NJ).  The two polymers (PY-PT60DE500 and PY-PT60DE) were 
added using separate K-Tron feeders (Sewell, NJ).  The film composition was determined 
by controlling the ratio of the feed rates into the extruder.  The end of the extruder 
featured a 0.02 × 6 inch sheet die and the extrudate was fed into a Leistritz 3-roll film 
stack, temperature controlled to 15 °C.  
Each large tablet was sandwiched between two polymer films on a hot plate set to 
100°C.  In the case of minitablets, two minitablets were sandwiched between the polymer 




the edges.  In the case of minitablets, the minitablets with a TPU layer were inserted into 
size 9 hard gelatin capsules to facilitate rat dosing. 
Tablet dissolution was performed using a Hanson (Chatsworth, CA) USP 
dissolution apparatus type II.  Each dissolution vessel was filled with 500 mL of 0.1N 
HCl, temperature controlled to 37°C, and the paddles were stirred at 75 rpm.  Three 
200 mg potency acyclovir matrix tablets and three 300 mg potency Gralise® tablets were 
added separately to each dissolution vessel.  Acyclovir concentration was measured using 
ultraviolet (UV) absorbance with a Pion (Billerica, MA) Rainbow™ fiber optic system 
equipped with a deuterium lamp and UV dip probes.  Gabapentin concentration was 
measured by taking aliquots, centrifuging them at 8000 rpm for 10 minutes, and 
transferring the supernatant to an HPLC.  The gabapentin samples were analyzed using 
an Agilent (Santa Clara, CA) high performance liquid chromatography apparatus, 
coupled to a UV spectrophotometer.  The chromatography used a Sigma-Aldrich Supelco 
(St. Louis, MO) Ascentis Express C18 reverse phase column with a 4.6 mm inner 
diameter, 100 mm length, and 2.7 µm silica particle size.  The mobile phase consisted of 
a gradient with mixtures of 0.1% (v/v) phosphoric acid and acetonitrile.  Over the course 
of the 6 minute run time, the mobile phase composition shifted from 5% acetonitrile to 
95% acetonitrile. 
Tablet swelling was measured by soaking the dosage form in 0.1N HCl, removing 
the dosage form at each time point, and measuring the dimensions using a caliper.  The 




4.3.2.2 Rat Gastric Retention Study 
In order to assess the capability of our formulations to retain in the stomach for 
extended durations, we performed an in vivo gastric retention study in 10-week old 
female Sprague-Dawley rats (CD(SD) rats, Charles River Laboratories, Raleigh, NC).  
The study was conducted according to an approved institutional animal care and use 
committee (IACUC) protocol at the University of Texas at Austin (protocol number 
AUP-2019-00153).  Animals were housed on a reversed 12-hour light cycle (lights on a 6 
AM), and food and water were provided ad libitum unless otherwise described.  One half 
of the rats were fasted starting 6 hours prior to dosage form administration and 
throughout the duration of the study, although they had free access to water.  To reduce 
stress in the fasted animals, fasting was introduced in 2-4 hour increments over 4 days 
leading up to the study until a maximum 12-hour fasting period was achieved.  On the 
day of the experiment, rats in the fasted group were transferred to a fresh cage 6 hours 
and 2 hours prior to dosing in order to minimize coprophagy during the study.  Each rat 
received an oral administration of a gelatin capsule containing the greater swelling 
formulation, the lesser swelling formulation, or a non-swelling control formulation 
containing only acyclovir minitablets.  Rat gastric contents were examined at 3, 6, 9, and 
24 hours after dosage form administration.  At each time point, three rats were sacrificed, 
and their stomachs were immediately excised, opened using a longitudinal incision, and 
investigated for the presence and disposition of the dosage form. 
4.3.2.3 Rat Pharmacokinetic Study 
In addition to the gastric retention study, we sought to investigate how our 
gastroretentive formulation affected drug release in an animal model.  A rat 




Pharmaron Beijing Co., Ltd. (protocol number PH-DMPK-TEX-19-001), in which PK 
properties of the greater swelling formulation and the non-swelling control formulation in 
male Sprague-Dawley rats were compared.  Three rats each were administered a 1.2 mg 
acyclovir dose of either formulation.  The rats were given free access to food and water 
throughout the duration of the study.  Blood samples were taken at 0.25, 0.5, 1, 2, 3, 6, 9, 
24, and 36 hours after dosing.  The bioanalytical assay was performed using a Shimadzu 
(Kyoto, Japan) high performance liquid chromatography apparatus, coupled to an AB 
Sciex (Framingham, MA) API 5500 LC-MS/MS mass spectrometer.  The 
chromatography used a Waters (Milford, MA) XSelect HSS T3 C18 reverse phase column 
with a 2.1 mm inner diameter, 50 mm length, and 2.5 µm silica particle size.  The mobile 
phase consisted of a gradient with mixtures of 0.1% (v/v) formic acid and acetonitrile.  
Over the course of the 2 minute run time, the mobile phase composition shifted from 5% 
acetonitrile to 95% acetonitrile. 
4.4 RESULTS 
4.4.1 Dosage Form Characterization 
We sought to develop an acyclovir matrix tablet that generally mimicked the drug 
release profile of gabapentin from Gralise®.  Specifically, we aimed to achieve a tablet 
release profile where approximately 80% of drug is released at 9 hours with 
approximately 100% released by 24 hours.  As shown in Figure 4.1, we developed an 
acyclovir matrix tablet formulation that closely matches the release profile of Gralise®.  
Our acyclovir formulation releases approximately 80% of the drug in 9 hours and 






Figure 4.1: Mean concentration over time (N = 3 ± SD) of Gralise® tablets overlaid with 
matrix acyclovir tablets. 
Since our acyclovir gastroretentive tablet design includes a matrix tablet 
surrounded by a hydrophilic TPU outer layer, we sought to understand the effect of the 
TPU layer itself on drug release.  Figure 4.2a compares the dissolution behavior of an 
acyclovir immediate release tablet without any TPU outer layer to the same immediate 
release tablet with a greater swelling 100% TPU2000 outer layer.  While the immediate 
release tablet without any TPU outer layer releases acyclovir rapidly with >80% released 
in 1.5 minutes, the tablet with a 100% TPU2000 outer layer exhibits substantially slower 
release.  By performing a linear regression on the linear portion of the dissolution curve 
between 1 and 2 hours (r2 = 0.99), we estimate an approximate release rate through the 








Figure 4.2: Mean concentration over time (N = 3 ± SD) of (a) immediate release and (b) 





Figure 4.2b shows the dissolution profile of the acyclovir controlled release 
matrix tablet without a TPU outer layer compared with the same tablet surrounded by a 
100% TPU2000 outer layer.  We performed a linear regression on the linear portion of 
both dissolution curves between 1.5 and 6.5 hours (r2 = 0.99) and estimated that the 
release rates of both formulations are approximately identical at 0.46 µg/mL/hr.  The only 
difference between the two dissolution curves shown in Figure 4.2b is an approximate 
30-minute delay in release associated with the tablet surrounded by the TPU outer layer.  
Figure 4.3 overlays the dissolution profiles of the same acyclovir matrix tablet 
without a TPU outer layer, with a greater swelling 100% TPU2000 outer layer, and with 
a lesser swelling 75% TPU500 outer layer.  All three formulations exhibit similar drug 
release profiles over the 24-hour time course, suggesting that drug release rate can be 
decoupled from the absence, presence, or type of TPU outer layer used. 
 
 
Figure 4.3: Mean concentration over time (N = 3 ± SD) of acyclovir controlled release 





Since expandable dosage forms retain in the stomach by increasing their size to 
dimensions unable to pass through the pylorus, we investigated the swelling behavior of 
Gralise® as a benchmark.  As described in Table 4.4, the tablet length, width, and 
thickness expanded approximately 30%, 20%, and 50%, respectively.  Notably, the two 
largest dimensions of the fully swollen tablet are approximately 21 mm and 12 mm. 
Table 4.4: Swelling behavior of a Gralise® tablet after soaking in 0.1N hydrochloric acid 
















0 16.2 10.2 6.9    ---  ---  --- 
0.25 17.3 10.5 7.4   7% 3% 7% 
0.5 17.9 11.5 7.9   10% 13% 14% 
0.75 17.9 11.8 7.8   10% 16% 13% 
1 18.2 12.2 8   12% 20% 16% 
2 18.6 12.5 9.3   15% 23% 35% 
4 18.9 12.4 10.8   17% 22% 57% 
6 19.8 12.1 10   22% 19% 45% 
8 20.2 12 10.2   25% 18% 48% 
10 20.9 11.9 10.4   29% 17% 51% 
 
Table 4.5 shows the swelling kinetics of acyclovir matrix tablets surrounded by 
greater swelling 100% TPU2000 and lesser swelling 75% TPU500 outer layers.  The dry 
tablet width and thickness are similar to Gralise®, but they swell considerably more 
when soaked in 0.1N HCl.  The greater swelling formulation achieves a hydrated length 
of 49 mm, a width 27 mm, and a thickness of 14 mm.  The lesser swelling formulation 





Table 4.5: Swelling behavior of controlled release acyclovir GR tablets with greater 
swelling and lesser swelling outer layers.  Relative size to pylorus column indicates 
whether at least 2 dimensions are smaller than, similar to, or larger than the estimated 
human pylorus diameter. 
Time 
(hr) 



















0 20.8 10.5 6.1 Smaller 19.7 8.1 6.2 Smaller 
0.5 33.0 20.4 20.4 Similar 33.1 15.0 9.2 Similar 
2 47.0 26.7 11.9 Larger 34.9 14.0 13.4 Similar 
3 48.5 28.4 12.7 Larger 35.3 16.2 11.0 Similar 
6 48.9 28.4 11.3 Larger 34.7 14.2 12.5 Similar 
8 49.4 27.4 14.2 Larger 35.4 16.6 12.6 Similar 
 
Our in vivo studies required scaling down of the acyclovir GR formulation to a 
scale suitable for rat consumption.  Consequently, acyclovir matrix minitablets were 
encapsulated in an outer layer of either greater swelling 100% TPU2000 or lesser 
swelling 75% TPU500 and inserted into size 9 hard gelatin capsules.  Table 4.6 describes 
the swelling behavior of both dosage forms in 0.1N HCl.  The rat pylorus was previously 
estimated to be 2-3 mm in diameter, therefore we aimed to design formulations for which 








Table 4.6: Swelling behavior of minitablet controlled release acyclovir GR rat dosage 
forms with greater swelling and lesser swelling outer layers.  Relative size to pylorus 
column indicates whether at least 2 dimensions are smaller than, similar to, or larger than 
the estimated rat pylorus diameter. 
Time 
(hr) 



















0 8.6 2.5 2.5 Similar 8.3 2.5 2.5 Similar 
0.5 17.1 6.3 6.3 Larger 14.2 4.4 4.4 Similar 
2 18.0 6.2 6.2 Larger 13.5 3.2 3.6 Similar 
3 19.0 5.1 5.6 Larger 12.8 3.9 3.5 Similar 
6 19.6 6.4 5.1 Larger 13.3 4.0 3.4 Similar 
8 19.0 6.2 5.0 Larger 13.0 4.0 3.5 Similar 
 
4.4.2 Rat Gastric Retention Study 
We investigated the ability of our GR dosage forms to retain in the stomach by 
administering the formulations to rats and, at specific time points, sacrificing them and 
inspecting their stomach contents.  Table 4.7 summarizes the observations of stomach 
retention for the two GR formulations of varying swelling extent and a non-swelling 
control in the fasted and fed states.  Representative pictures of the excised stomach and 
isolated dosage form for each formulation, prandial state, and time point are provided in 
Appendix C:.  Two animals were removed from the study due to dosing error (i.e., 
potential release of capsule in mouth, which led to chewing or expelling the dosage form 
from the mouth in the cage).  Consequently, we denoted these observations with a N/A in 
the table and excluded them from subsequent analysis.  We summarized the findings at 
each time point and prandial state by reporting the percent of rats for which the dosage 




stomach for extended durations, whereas the non-swelling control does not retain in the 
stomach at 6 hours. 
Table 4.7: Summary of dosage form retention in each rat during gastric retention study.  
N/M indicates that the replicate was not measured.  N/A means not applicable and 
indicates that we were unable to verify that the rat swallowed the capsule, resulting in the 
















Greater Swelling Fed 3 Yes Yes Yes 100% 
Greater Swelling Fed 6 Yes Yes Yes 100% 
Greater Swelling Fed 9 Yes Yes Yes 100% 
Greater Swelling Fed 24 No No No 0% 
Lesser Swelling Fed 3 N/A Yes Yes 100% 
Lesser Swelling Fed 6 Yes Yes Yes 100% 
Lesser Swelling Fed 9 Yes Yes No 67% 
Lesser Swelling Fed 24 No Yes No 33% 
Negative Control Fed 6 No No N/M 0% 
Greater Swelling Fasted 3 Yes Yes Yes 100% 
Greater Swelling Fasted 6 N/A Yes Yes 100% 
Greater Swelling Fasted 9 No No No 0% 
Greater Swelling Fasted 24 No No No 0% 
Lesser Swelling Fasted 3 Yes Yes Yes 100% 
Lesser Swelling Fasted 6 No No No 0% 
Lesser Swelling Fasted 9 No No No 0% 
Lesser Swelling Fasted 24 No No Yes 33% 
Negative Control Fasted 6 No No N/M 0% 
 
Figure 4.4 allows for the comparison of the GR formulations across time and 
prandial state.  The greater swelling formulation exhibited better retention behavior in 
both the fasted and fed states than the lesser swelling formulation.  In the fasted state, the 




stomach at 6 hours and beyond.  In contrast, the greater swelling formulation retained at 6 
hours in all rats and did not retain in the stomach at 9 hours and beyond.  In the fed state, 
the greater swelling formulation retained in all rats through 9 hours after dosage 
administration, yet the lesser swelling formulation only retained in 2 out of 3 rats at the 9-
hour time point.  The greater swelling formulation had emptied the stomach by 24 hours 
in both the fasted and fed states.  However, the lesser swelling formulation retained in the 
stomach of 1 of 3 rats in both the fasted and fed states. 
 
 
Figure 4.4: Summary of dosage form retention during gastric retention study.  The data 
are presented as the percent of total rats studied at the particular time point and prandial 
state for which a dosage form was observed to be retained in the stomach. 
Among the observations where the dosage form was retained in the rat stomach, 
we also recorded whether it remained largely intact compared to a reference standard 




over time for different formulations and prandial states.  The data are presented as the 
percent of rats with the dosage form largely intact in the stomach out of the instances in 
which the dosage form was retained.  Therefore, individual observations in which no 
dosage form was retained in the stomach are excluded from this analysis.  Although 
neither formulation remains intact in all observed rats, the lesser swelling formulation 
tends to maintain integrity over the greater swelling formulation in both the fasted and 
fed states.  Additionally, each formulation is more likely to remain intact in the rat 
stomach in the fasted state than in the fed state.  Finally, the greater swelling formulation 
is no longer intact in the rat stomach by 9 hours in both prandial states, whereas the lesser 
swelling formulation largely remains intact when it is retained in the stomach.  
 
 
Figure 4.5: Summary of dosage form integrity during gastric retention study.  The data 
are presented as the percent of total rats studied at the particular time point and prandial 
state for which a dosage form was observed to be intact among those rats which retained 




4.4.3 Rat pharmacokinetic study 
We sought to verify that the controlled release matrix tablet surrounded by a TPU 
outer layer would result in a gastroretentive dosage form that slowly released drug over 
the course of multiple hours.  Consequently, we measured the pharmacokinetic properties 
of our greater swelling formulation and the non-swelling control in rats.  Figure 4.6 
shows the plasma concentration as a function of time for the two formulations.  The data 
show that the greater swelling formulation exhibits a substantially delayed tmax compared 
with the non-swelling control.  The key pharmacokinetic parameters are described in 
Table 4.8, illustrating that the area under the curve (AUC) of the two formulations are 
comparable, with the greater swelling formulation achieving 75% the AUC of the non-
swelling control formulation. 
 
 
Figure 4.6: Mean pharmacokinetic profile (N = 3 ± SD) of acyclovir formulations 




Table 4.8: Key acyclovir mean pharmacokinetic parameters (N = 3 ± SD) from the rat 
study comparing the plasma concentration-time profiles of the greater swelling 
formulation and the non-swelling control formulation. 
Formulation Non-Swelling Control Greater swelling 
AUC0-36hr (h*ng/mL) 245.5 ± 27.10 184.5 ± 154.2 
Relative AUC – 75% 
Cmax (ng/mL) 92.07 ± 28.28 35.50 ± 24.87 
tmax (hr) 1.33 ± 0.577 4.67 ± 2.31 
 
4.5 DISCUSSION 
We sought to develop a gastroretentive dosage form that differentiates from 
others [60–67] in that it can decouple drug release rate from gastric retention properties.  
Our dosage form design separates the two properties by relying on the matrix tablet 
formulation composition to determine drug release behavior and emphasizes the swelling 
behavior of the hydrophilic TPU outer layer in order to retain in the stomach.  In this 
study, we analyzed each of the two major design components of the dosage form by 
comparing an immediate release acyclovir tablet to one surrounded by the TPU outer 
layer and by comparing a controlled release matrix tablet without a TPU layer to one 
surrounded by the TPU outer layer.   
Although we observed in Figure 4.2a that an IR acyclovir tablet releases within a 
few minutes, the IR tablet with TPU outer layer slows the release of acyclovir.  This 
finding aligns with a previous study showing that drug diffusion through a hydrophilic 
TPU membrane was constrained but relatively rapid [47].  However, the drug diffusion 
rate through the TPU outer layer (2.6 µg/mL/hr) is substantially faster than the CR 
acyclovir matrix tablet release rate (0.46 µg/mL/hr) shown in Figure 4.2b.  The 




that one would expect for a typical once daily controlled release tablet, as illustrated by 
the comparison to Gralise® in Figure 4.1.  Since drug release rate through the TPU outer 
layer is greater than 5 times its expected release rate from a typical once daily matrix 
tablet, we believe that the matrix tablet will generally be the determinant of drug release 
rate from the dosage form.  Our data further support this hypothesis, given that the CR 
acyclovir matrix tablet surrounded by the TPU outer layer exhibits approximately the 
same release rate as the CR acyclovir matrix tablet without a TPU outer layer (Figure 
4.2b).  We attribute the 30-minute lag time between the two dissolution curves to the 
hydration time of hydrophilic TPU polymer prior to the formation of a continuous pore 
network.  Consequently, we have demonstrated a dosage form design that effectively 
decouples the duration of gastric retention from the rate of drug release from the tablet. 
Elements of our dosage form design approach have been investigated by other 
researchers.  Deshpande et al. reported on the development of a gastroretentive delivery 
system in which a core tablet is surrounded by an outer polymer layer [31].  The general 
design strategy is similar to ours, however there are several key differences.  Their design 
relies on the core tablet to swell, whereas the polymer layer functions only as a permeable 
membrane that promotes gelling and tensile strength.  Therefore, their dosage form does 
not decouple drug release from swelling behavior, making it challenging to develop a 
dosage form that swells substantially while maintaining slow drug release.  In addition, 
investigators have extensively studied the role of superporous hydrogel composites for 
gastric retention [68–70].  Although they have synthesized their own polymers, their 
approach is similar to ours in that they rely on rapid and extensive swelling, in addition to 
mechanical strength, of the polymer hydrogels to retain in the stomach.  However, their 




core tablet itself.  Therefore, the approach has not yet been shown to fully decouple 
swelling behavior and release rate. 
Sufficient expansion in at least two dimensions is required to retain the dosage 
form in the stomach.  The expanded length necessary to avoid emptying from the 
stomach as part of the MMC has been widely debated.  The estimate provided by Munk 
et al. of 12.8 ± 7.0 mm implies that 67% of the population has a relaxed pylorus diameter 
ranging between 5.8 mm and 19.8 mm, suggesting a broad distribution of sizes [34].  We 
found that the two largest dimensions of swollen Gralise® are 21 and 12 mm (Table 4.5), 
which suggests that either the pylorus estimates are inaccurate or that the delivery 
mechanism of Gralise® is not expandable gastric retention.  Furthermore, the product’s 
Food and Drug Administration (FDA) Center for Drug Evaluation and Research Cross 
Discipline Team Leader Review indicates that the reviewers questioned if the product 
should be classified as an extended-release product [71].  While the FDA’s specific 
rationale has been redacted, it is reported that Gralise® takes advantage of changes to the 
MMC cycle in the fed state, where Phase III contractions are significantly less than in the 
fasted state [35].  For example, a clinical study comparing the effect of fasted, low-fat, 
and high-fat prandial states on the pharmacokinetics of Gralise® found that the geometric 
mean tmax increased from 3.5 hr (fasted) to 6.0 hr (low-fat fed) to 9.0 hr (high-fat fed) 
[72].  Consequently, it remains unclear what role the swelling of Gralise® plays in its 
gastric retention, and it is possible that the 12 mm hydrated dimension is insufficient to 
retain the tablet for extended durations.   
We developed two GR formulations based on the same design approach, using the 
same matrix tablet composition, but surrounding it with two different hydrophilic TPU 




the greater swelling dosage form expands to a size well beyond pylorus diameter 
estimates in two dimensions, whereas the lesser swelling dosage form expands to a size 
where the second largest dimension is in the approximate range of the relaxed pylorus 
diameter.  The GR dosage forms used for the rat studies were intended to mimic the 
human dosage forms and exhibit similar swelling behavior.  The rat relaxed pylorus 
diameter has been estimated at 2-3 mm [59].  As illustrated in Table 4.6, the greater 
swelling dosage form using in rat studies expands to much larger than 3 mm in all 
dimensions, whereas the lesser swelling dosage form used in rat studies expands to 
approximately the same estimated size as the rat pylorus. 
It is worth noting that our reported dimensions reflect the expanded dosage form 
size unconstrained by gastric forces.  Since the dosage form is realistically under stress 
from gastric forces, and because it is unclear what dosage form strength is necessary to 
ensure stomach retention, it was necessary to investigate the in vivo performance of our 
formulations.  There is no ideal animal model for the human gastrointestinal tract, with 
each animal’s gastrointestinal attributes exhibiting both similarities and differences to 
humans [73].  Although dogs are routinely used to assess the performance of formulation 
technologies, they exhibit some key differences with humans that may limit their ability 
to model gastroretentive formulation performance in humans.  Gastric emptying time is 
comparable between humans and dogs in the fasted state, but extended gastric residence 
time has been observed under fed conditions with small non-disintegrating dosage forms 
ranging from 5-13.3 hours in dogs compared with 2.6-4.8 hours in humans [74].  
Additionally, the substantially shorter intestinal transit time in dogs contrasted with 
humans (111 ± 17 min in dogs vs 238 ± 14 min in humans) may result in underprediction 




exhibit 6-fold greater gastric forces than humans in the fasted state and 4-fold greater 
gastric forces than humans in the fed state [76].  A GR formulation whose retention 
mechanism is dependent on having sufficient strength to withstand gastric forces may not 
be retained in a canine stomach whereas it could easily be retained in a human stomach.   
In contrast to dogs, rats exhibit comparable intestinal transit times to humans (2.6-
3.3 hours in rats vs 3.5-4.5 hours in humans) [77].  Although fasted rats exhibit 
approximately 10-fold lower gastric forces than fasted humans, fed state rats exhibit 
comparable gastric forces to humans [76].  However, one area where rats do not model 
humans substantially better than dogs is with respect to gastric emptying time.  In a study 
investigating the gastrointestinal transit time of pellets in rats, Tuleu et al. found that 
approximately 50% of the stomach contents were still present after 3 hours and they 
observed that it took 6 hours following food intake for >90% of the stomach contents to 
empty [77].  We incorporated this difference into our study design by extending the time 
points out beyond what one would typically investigate for a human gastroretentive 
formulation.  We examined the stomach contents of the rats out to longer than 9 hours to 
ensure sufficient gastric retention, rather than the 4-6 hours we might anticipate for a 
human GR formulation.  Similarly, the presence of our non-swelling control formulation 
was observed at 6 hours for comparison to our GR dosage forms, rather than at 3-4 hours 
we might have done for a human GR formulation. 
Both GR formulations of varying TPU swelling extent retained in the rat stomach 
for extended durations, whereas the non-swelling control formulation was consistently 
absent from the stomach at the 6 hour time point investigated (Table 4.7).  This suggests 
that gastric retention may be possible for expandable dosage forms in which two 




However, we did observe differentiation between formulations and prandial states with 
regard to retention time (Figure 4.4).  The greater swelling formulation was retained for a 
longer duration than the lesser swelling formulation in both the fasted and fed states.  It is 
possible that the retention time of GR dosage forms that expand to sizes within the range 
of the pylorus diameter is related to the timing of the MMC Phase III wave, as has been 
proposed for Gralise® [67].  In contrast, the gastric retention times of dosage forms that 
expand to a size substantially larger than the relaxed pylorus diameter, such as our greater 
swelling formulation, are less sensitive to MMC waves. 
Interestingly, each formulation was retained in the stomach for a longer duration 
in the fed state than in the fasted state.  This phenomenon may be due to delayed gastric 
emptying in the fed state, however we would expect emptying from the rat stomach to be 
complete by 9 hours even in the fed state [77].  Better gastric retention in the fed state is 
also consistent with the Gralise® behavior, where the investigators relied on lower gastric 
forces during the fed state MMC Phase III wave than in the fasted state [67].  We would 
expect lower gastric forces to result in extended stomach retention. 
We verified that the gastric retention of our dosage form results in delayed tmax 
and similar AUC compared with the control formulation by conducting a 
pharmacokinetic study (Figure 4.6).  Acyclovir is poorly permeable and has limited 
absorption in the lower gastrointestinal tract [51,53].  Consequently, one would expect 
that a conventional controlled release formulation designed to slowly release drug as it 
travels through the gastrointestinal tract may exhibit delayed tmax but with a reduced AUC 
compared with an immediate release reference.  Although our control formulation 
contains high molecular weight hydroxypropyl methylcellulose polymer, we found it to 




minitablets were freely dispersed in dissolution media, they exhibited immediate release 
behavior, likely due to the high surface area of individual minitablets.  Consequently, our 
control formulation exhibited immediate release behavior.  As shown in Table 4.8, our 
greater swelling formulation exhibits a significantly delayed tmax, but with similar AUC 
to the control formulation.  We propose that this outcome is possible because we have 
effectively retained the dosage form in the rat stomach for an extended duration as it 
slowly released drug. 
Although the greater swelling formulation was more often retained in the 
stomach, we found that the lesser swelling formulation remained intact more often 
(Figure 4.5).  While the polymer films used for the two formulations exhibit similar 
rigidity in the dry state, the volume of the 100% TPU2000 polymer used in the greater 
swelling formulation contains substantially more water when hydrated (Table 4.6).  
Consequently, the greater swelling formulation is substantially softer than the lesser 
swelling formulation, which may explain why it is less likely to remain intact after being 
subjected to gastric forces for extended lengths of time.  Better dosage form integrity of 
the lesser swelling formulation may result in more consistent drug release rates than the 
greater swelling formulation, highlighting that there may be an optimal set of polymer 
properties between swelling extent and strength. 
We observed that the fasted state resulted in greater dosage form integrity over 
that in the fed state, regardless of the formulation (Figure 4.5).  Changes in stomach pH 
between prandial states are unlikely to drive changes in dosage form integrity, as the 
polymer is nonionic [58].  Given that gastric forces are expected to be lower in intensity 




that food particles prevalent in the stomach of fed state animals may act as milling media, 
breaking apart the dosage form over time. 
A key design aspect of our GR dosage form was that, despite targeting gastric 
retention for extended durations, it should exit the stomach by 24 hours.  If it were to be 
retained in the GI tract for especially longer durations, there would be an increased risk of 
gastrointestinal obstruction, as has been observed in a range of instances including 
ingestible electronic devices [78], percutaneous feeding tubes [79], and intragastric 
balloons for weight loss [80].  Therefore, we sought to avoid this risk by designing the 
dosage form to retain for extended durations, but less than 24 hours.  As shown in Figure 
4.4, the greater swelling formulation was successfully cleared from the stomach by 24 
hours for all rats in both the fasted and fed states.  The lesser swelling formulation 
remained in the stomach of one out of three rats at the 24 hour time point for both the 
fasted and fed states.  Since the greater swelling formulation is softer, its mechanical 
properties may be responsible for its tendency to clear the stomach by 24 hours more 
consistently. 
4.6 CONCLUSION 
We designed dosage forms of acyclovir that could be administered less frequently 
by being retained in the stomach and releasing drug over an extended time period.  We 
approached the challenge by developing a conventional controlled release matrix tablet to 
sustain the release of acyclovir over the target time duration and surrounding the matrix 
tablet with an outer layer composed of hydrophilic TPU that does not substantially 
contribute to controlled release of the drug.  When the tablet is hydrated, the hydrophilic 




demonstrated that formulating acyclovir in such a dosage form will retain the tablet in the 
stomach for extended durations in both the fasted and fed states as it slowly releases drug, 
allowing for similar AUC but delayed tmax relative to a non-gastroretentive control.  
Unlike many other gastroretentive formulations, this dosage form design decouples drug 
release rate from gastric retention time, allowing the two parameters to be modulated 
independently based on the needs of a particular product.  Our direct observation of the 
dosage form retention and disposition in the stomach allowed for a high confidence 
assessment of the impact of polymer swelling extent and prandial state on both the 
dosage form integrity and retention time.  Future work will focus on developing 
predictive mechanical tests intended to simulate the gastric forces imparted on the dosage 
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Appendix A: Supplementary Information to Chapter 2  
 
A.1 POLYMER FILM FABRICATION DETAILS 
As part of the study described in Chapter 2, we varied the independent extrusion 
parameters (barrel temperature profile, screw speed, screw profile, and feed rates) in 
order to affect dependent process parameters, as shown in Table A.1.  Mixture 
composition was calculated by dividing the feed rate of the hydrophilic thermoplastic 
poly(urethane) (TPU) by the total feed rate. Melt temperature was measured directly by a 
flush-mounted thermocouple at the die adapter. Specific mechanical energy was 
calculated by dividing the measured screw motor power draw by the total feed rate. 
Estimated breakthrough time is a measure of residence time. Briefly, we added color-
dyed poly(ethylene) pellets to the extruder feed port while the process was running at 
steady state and recorded the time until the appearance of color was observed at the die. 
Thus, breakthrough time represents the leading edge of the residence time distribution. 
Breakthrough time was measured at several key runs. It was found to vary only with 
screw profile and total feed rate (not temperature or screw speed). Therefore, 
breakthrough time for most runs was estimated based on measurements of other runs 












Table A.1: Independent process parameters studied on Leistritz 18 mm twin-screw 
extruder, along with corresponding dependent process parameters that are used to assess 
impact on mixing and release. 































3.015 0 A A 200 0.6 0.00% 193 116 0.20 
5.547 0.368 B B 350 1.3 6.22% 176 46 0.22 
5.643 0.393 A A 400 1.4 6.51% 213 116 0.23 
5.241 0.733 A A 400 1.4 12.27% 212 116 0.23 
5.253 0.741 B B 350 1.2 12.36% 175 46 0.20 
4.494 1.473 B B 300 1.2 24.69% 173 46 0.20 
4.461 1.476 A B 444 1.8 24.86% 172 116 0.30 
2.214 0.736 A B 200 0.8 24.95% 170 116 0.27 
2.229 0.743 A A 200 0.6 25.00% 203 116 0.20 
3.009 2.999 A B 400 1.7 49.92% 171 116 0.28 
1.467 1.466 A A 400 1.6 49.98% 176 108 0.55 
2.973 2.986 B B 300 1.1 50.11% 172 46 0.18 
1.485 1.503 A B 200 0.7 50.30% 167 116 0.23 
1.473 1.526 A A 200 0.6 50.88% 179 116 0.20 
1.401 1.62 B B 140 0.9 53.62% 165 127 0.30 
1.407 1.656 A B 600 2.2 54.06% 166 83 0.72 
1.356 1.637 B B 160 0.9 54.69% 165 127 0.30 
1.353 1.656 A A 400 1.5 55.03% 176 108 0.50 
1.239 1.792 B B 160 0.9 59.12% 164 127 0.30 
1.209 1.781 A A 400 1.4 59.57% 175 108 0.47 
1.182 1.814 A B 600 2.3 60.55% 173 83 0.77 
1.071 1.914 B B 160 0.8 64.12% 163 127 0.27 
1.065 1.932 A A 400 1.4 64.46% 175 108 0.47 
1.047 1.971 A B 600 2.2 65.31% 166 83 0.73 
0.915 2.068 A A 400 1.4 69.33% 175 108 0.47 
0.909 2.102 A B 600 2.3 69.81% 166 83 0.76 
0.897 2.076 B B 160 0.8 69.83% 164 127 0.27 
0.756 2.239 A A 400 1.4 74.76% 175 108 0.47 
0.753 2.243 A A 200 0.5 74.87% 179 116 0.17 
1.494 4.482 A B 350 1.5 75.00% 171 116 0.25 




A.2 SOLID-STATE NUCLEAR MAGNETIC RESONANCE DETAILS 
Most previous studies of pharmaceutical dispersions have used 13C-detected 
relaxation time measurements for making use of the resolved carbon peak of the active 
pharmaceutical ingredient and polymer. In this study, the hydrophilic and hydrophobic 
TPU polymers exhibit fully overlapped carbon peaks as shown in Figure A.1.  Therefore, 
we established a 1H-detected method for efficiently evaluating the miscibility of the two 
polymer components, as described in section 2.3.2.2. An example is illustrated in Figure 
A.2.  1H ssNMR spectra of extruded pure hydrophobic TPU, pure hydrophilic TPU, and a 
mixture (50.11% hydrophilic content) are shown in the left column of A, B, and C, 
respectively. The 1H spectrum of the TPU mixture sample can be deconvoluted to two 
components by utilizing the weight percentages (i.e., 49.89% and 50.11% for 
hydrophobic and hydrophilic TPUs, respectively).  
 
 
Figure A.1: 13C nuclear magnetic resonance spectra of the hydrophilic (top) and 





Figure A.2: 1H spectra (left column) of extruded hydrophobic TPU (A), hydrophilic TPU 
(B), and TPU mixture with 50.11% (w/w) hydrophilic TPU (C), and their corresponding 
relaxation curves of T1 (right column) and T1ρ (middle column). The decovoluted pure 
hydrophobic (red and dashed) and pure hydrophilic (blue and dashed) components, and 
their added spectrum (black dashed), are shown in C, which matches well with the 






Appendix B: Supplementary Information to Chapter 3  
 
B.1 DRUG APPARENT PERMEABILITY MEASUREMENT THROUGH MEMBRANES 
As part of the study described in Chapter 3, we measured drug apparent 
permeability through polymer membranes.  A polymer membrane of each sample was cut 
using a hammer-driven hole punch and placed into a membrane holder.  The membrane 
holder was positioned between identical donor and acceptor glass chambers.  Cross-type 
magnetic stir bars were used to ensure good mixing within the chamber.  The drug 
solution was intended to model the core of the reservoir implant, while the polymer film 
was intended to model the rate-controlling membrane of the implant.  A drug solution in 
a buffer of defined pH was added to the donor chamber, while pure buffer was added to 
the acceptor chamber.  Ultraviolet absorbance was measured in the acceptor chamber 
using a Pion Rainbow™ fiber optic system (Billerica, MA) equipped with a deuterium 
lamp and UV dip probes.  Figure B.1, Figure B.2, and Figure B.3 show representative 






Figure B.1: Emtricitabine concentration (N = 3 ± SD) in a diffusion cell receptor chamber 
as a function of run time through a 100% hydrophobic poly(urethane) membrane.  The 
donor concentration in the diffusion cell was 1000 µg/mL.  The steady-state diffusion 
rate was used to determine membrane permeability. 
 
 
Figure B.2: Metoprolol concentration (N = 3 ± SD) in a diffusion cell receptor chamber 
as a function of run time through a 100% hydrophobic poly(urethane) membrane.  The 
donor concentration in the diffusion cell was 400 µg/mL.  The steady-state diffusion rate 






Figure B.3: Ibuprofen concentration (N = 3 ± SD) in a diffusion cell receptor chamber as 
a function of run time through a 100% hydrophobic poly(urethane) membrane.  The 
donor concentration in the diffusion cell was 11.8 µg/mL.  The steady-state diffusion rate 






Appendix C: Supplementary Information to Chapter 4  
 
C.1 RAT GASTRIC RETENTION STUDY 
We investigated the ability of our GR dosage forms to retain in the stomach by 
administering the formulations to rats and, at specific time points, sacrificing them and 
inspecting their stomach contents.  Representative pictures of the excised stomach and 
isolated dosage form for each formulation, prandial state, and time point are provided in  
 
(a)   (b)  
Figure C.1: Representative excised stomach (a) and isolated dosage form (b) from a 
fasted rat administered the greater swelling GR formulation and sacrificed 3 hours 
following dosing.  Measurements are provided in cm.  The yellow “E” indicates where 




(a)  (b)  
Figure C.2: Representative excised stomach (a) and isolated dosage form (b) from a 
fasted rat administered the greater swelling GR formulation and sacrificed 6 hours 
following dosing.  Measurements are provided in cm.  The yellow “E” indicates where 
the esophagus is located and the red “P” indicates where the pylorus is located. 
 
Figure C.3: Representative excised stomach from a fasted rat administered the greater 
swelling GR formulation and sacrificed 9 hours following dosing.  No dosage form was 
found.  Measurements are provided in cm.  The yellow “E” indicates where the 





Figure C.4: Representative excised stomach from a fasted rat administered the greater 
swelling GR formulation and sacrificed 24 hours following dosing.  No dosage form was 
found.  Measurements are provided in cm.  The yellow “E” indicates where the 
esophagus is located and the red “P” indicates where the pylorus is located. 
(a)  (b)  
Figure C.5: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the greater swelling GR formulation and sacrificed 3 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 




(a)  (b)  
Figure C.6: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the greater swelling GR formulation and sacrificed 6 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 
esophagus is located and the red “P” indicates where the pylorus is located. 
(a)  (b)  
Figure C.7: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the greater swelling GR formulation and sacrificed 9 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 





Figure C.8: Representative excised stomach from a fed rat administered the greater 
swelling GR formulation and sacrificed 24 hours following dosing.  No dosage form was 
found.  Measurements are provided in cm.  The yellow “E” indicates where the 
esophagus is located and the red “P” indicates where the pylorus is located. 
(a)  (b)  
Figure C.9: Representative excised stomach (a) and isolated dosage form (b) from a 
fasted rat administered the less swelling GR formulation and sacrificed 3 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 





Figure C.10: Representative excised stomach from a fasted rat administered the less 
swelling GR formulation and sacrificed 6 hours following dosing.  No dosage form was 
found.  Measurements are provided in cm.  The yellow “E” indicates where the 
esophagus is located and the red “P” indicates where the pylorus is located. 
 
Figure C.11: Representative excised stomach from a fasted rat administered the less 
swelling GR formulation and sacrificed 9 hours following dosing.  No dosage form was 
found.  Measurements are provided in cm.  The yellow “E” indicates where the 




(a)  (b)  
Figure C.12: Representative excised stomach (a) and isolated dosage form (b) from a 
fasted rat administered the less swelling GR formulation and sacrificed 24 hours 
following dosing.  Measurements are provided in cm.  The yellow “E” indicates where 
the esophagus is located and the red “P” indicates where the pylorus is located. 
(a)  (b)  
Figure C.13: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the less swelling GR formulation and sacrificed 3 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 




(a)  (b)  
Figure C.14: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the less swelling GR formulation and sacrificed 6 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 
esophagus is located and the red “P” indicates where the pylorus is located. 
(a)  (b)  
Figure C.15: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the less swelling GR formulation and sacrificed 9 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 




(a)  (b)  
Figure C.16: Representative excised stomach (a) and isolated dosage form (b) from a fed 
rat administered the less swelling GR formulation and sacrificed 24 hours following 
dosing.  Measurements are provided in cm.  The yellow “E” indicates where the 
esophagus is located and the red “P” indicates where the pylorus is located. 
C.2 MECHANICAL TESTING OF GASTRORETENTIVE DOSAGE FORMS 
C.2.1 Introduction 
During our study described in Chapter 4, our reported dosage form dimensions 
reflect the expanded dosage form size unconstrained by gastric forces.  Since the dosage 
form is realistically under stress from gastric forces, we performed mechanical testing on 
the dosage forms to assess its strength under stress.  Sufficient strength in at least two 
dimensions is required to prevent deformation of the expanded dosage form such that it 
may be emptied as part of the MMC.  However, the reported forces that gastroretentive 
formulations encounter in the stomach are varied.  Moreover, although much research 
efforts has been dedicated to simulating gastric forces in vitro, the vast majority of the 
work has been focused on studying the effect of gastric forces on drug release behavior 
rather than on stomach retention [1–7]. Vassallo et al. coupled a load cell to a balloon 




emptying of solids over 2 hours [8].  Kamba et al. attempted to estimate the gastric forces 
on a tablet by preparing tablets of defined crushing strength, dosing them to healthy 
subjects, and observing whether the tablets were destroyed by the stomach indicated by 
the release of drug [9].  They observed all tablets with a crushing strength of 1.5 N were 
crushed, but tablets with a crushing strength of 1.89 N were crushed by the stomachs of 
only 2 of 5 subjects.  Tablets with a crushing strength of 3.04 N were not crushed by the 
stomachs of any subject investigated.  Marciani et al. prepared 12.7 mm diameter agar gel 
beads with fracture strengths ranging from 0.15-0.90 N and assessed their time to 
breakage by measuring their gastric residence time residence time in humans using 
magnetic resonance imaging [10].  They found that all beads were eventually cleared 
from the stomach, but that those with a strength >0.65 N exhibited longer residence time. 
Cassilly et al. measured the pressure, among other parameters, encountered by a 
SmartPill recording device as it passed through the human gastrointestinal tract [11].  
They observed peak pressures around 200 mm Hg associated with Phase III of the MMC, 
which can be estimated at 85 N force given the dimensions of the SmartPill.  Their work 
was recapitulated by Parkman and Jones using the SmartPill and they reported similar 
peak pressure values [12].  Laulicht et al. utilized a Hall array sensor technology to track 
the position and orientation of magnetic pills, which were then used to make force 
calculations [13].  They reported a maximum gastric motive force of 3014 dynes, which 
is approximately 0.03 N.  A peak gastric force variance of 0.03 – 85 N is dramatic and 
speaks to the uncertainty in these estimations.  For example, most studies assume that the 
entire surface area of their chosen probe (i.e., balloon, tablet, pill, etc.) is in contact with 




As previously described, multiple publications describe human stomach forces of 
varying levels, including varying orders of magnitude.  Researchers also propose varying 
in vitro tests to assess retention of a dosage form in the stomach, although most 
publications related to gastric forces focus on their effects on drug dissolution, rather than 
on deformation/size changes relevant to stomach retention.  Consequently, we found no 
clear consensus on the most relevant in vitro test to assess gastric retention or what 
success criteria would be for such a test.  Therefore, we sought to compare in vivo gastric 
retention observations in rats to the data from in vitro tests, identifying suitable in vitro 
gastric retention test and success criteria. 
C.2.2 Methods 
We developed two different mechanical tests using an Instron (Norwood, MA) 
5544 Tensile/Compressive Machine and custom-made three-dimensional printed 
poly(lactic acid) parts.  Our “normal” mechanical test used a custom-made three-
dimensional printed funnel with an upper diameter of 27.5 mm and a lower diameter of 
20 mm, as shown in Figure C.17a.  The funnel height was 10.5 mm, whereas the overall 
fixture raised the funnel portion higher from the surface and was 68.5 mm.  The probe 
attached to the Instron crosshead was a 15.9 mm diameter cylinder.  The hydrated dosage 
form was placed in the funnel after soaking in 0.1N HCl for a specific duration, oriented 
such that the smaller dimension was perpendicular to the funnel opening, as shown in 
Figure C.17a.  The crosshead and probe approach the tablet as a normal force at a 
displacement rate of 10 mm/sec.  The test is meant to represent the normal force required 




Our “compression” mechanical test used a custom-made three-dimensional 
printed container and probe.  The container was 62 mm long, 16 mm wide, and 36 mm 
high, as shown in Figure C.17b.  The narrow width ensures that the dosage form is 
oriented on its side.  The probe attached to the Instron is 55 mm long, 12 mm wide, and 
35 mm high.  The hydrated dosage form was placed in the container after soaking in 0.1N 
HCl for a specific duration.  The crosshead and probe approach the tablet as a normal 
force at a displacement rate of 10 mm/sec.  The test is meant to represent the compressive 
peristaltic forces of the stomach. 
 
(a)  (b)  
Figure C.17: Normal (a) and compression (b) mechanical test components. 
C.2.3 Results and Discussion 
The curves of force as a function of displacement for the normal and compression 
mechanical tests of the greater swelling formulation are shown in Figure C.18 after 1 




soaking.  In each figure, the red horizontal line corresponds to the 0.03 N maximum force 
threshold described by Laulicht et al. [13].  The green vertical line related to the 
compression mechanical test and represents a displacement of 17 mm from the top of the 
container, representing a 20 mm relaxed pylorus diameter.  We observed a substantial 
softening of the polymer layer between 1 and 3 hours, as measured by the force-
displacement curve of both the normal and compression mechanical tests.  However, we 
observed no substantial change in the force required to displace the dosage form from 3 
to 6 hours using that test.  At all time points, we found that the force required to push the 
dosage form through the funnel orifice of the normal mechanical test was substantially 
greater than 0.03 N (from 0.5 N to >2 N).  Similarly, we found that the force required to 
compress the dosage form to less than 20 mm in width exceeded 0.03 N at all time points, 
although it required less than 0.3 N. 
The curves of force as a function of displacement for the compression mechanical 
tests of the lesser swelling formulation after 1 hour, 3 hours, and 6 hours of soaking in 
0.1N HCl are shown in Figure C.21.  The normal mechanical test was not possible for 
this dosage form because the shorter dimension was less than 20 mm for all swollen 
samples and the dosage form falls through the funnel immediately.  Similar to the 
previous figures, the red horizontal line corresponds to the 0.03 N maximum force 
threshold described by Laulicht et al [13].  The green vertical line related to the 
compression mechanical test and represents a displacement of 17 mm from the top of the 
container, representing a 20 mm relaxed pylorus diameter.  We observed a similar trend 
to the greater swelling formulation of polymer layer softening, with less force required to 
displace the dosage form.  However, there were no recordable forces exerted on the probe 






Figure C.18: Normal and compression mechanical tests on the greater swelling (100% 
TPU2000) dosage form after 1 hour soaking in 0.1N HCl. 
 
Figure C.19: Normal and compression mechanical tests on the greater swelling (100% 





Figure C.20: Normal and compression mechanical tests on the greater swelling (100% 
TPU2000) dosage form after 6 hours soaking in 0.1N HCl. 
 
 
Figure C.21: Compression mechanical test on the lesser swelling (75% TPU500) dosage 





We developed two mechanical tests intended to simulate mechanical forces in the 
stomach.  The normal mechanical test is less physiologically relevant to the mode of 
gastric forces that a dosage form encounters, however it is a more well-defined test.  The 
compression mechanical test is closer to the peristaltic motions of the stomach, but 
potentially less reproducible.  Ultimately, we were unable to effectively correlate our 
mechanical test data to the rat gastric retention study data.  Although the two 
formulations retained to different extents in the rat gastric retention study, it is possible 
that there was insufficient differentiation to properly develop an in vitro-in vivo 
correlation.  Future work will focus on the development of alternative mechanical tests 
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